CN112933118A - Compositions and methods for treating the eye - Google Patents
Compositions and methods for treating the eye Download PDFInfo
- Publication number
- CN112933118A CN112933118A CN202011302835.4A CN202011302835A CN112933118A CN 112933118 A CN112933118 A CN 112933118A CN 202011302835 A CN202011302835 A CN 202011302835A CN 112933118 A CN112933118 A CN 112933118A
- Authority
- CN
- China
- Prior art keywords
- pichia
- optionally
- composition
- extract
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention is directed to compositions and methods for treating the eye. The present invention relates to compositions comprising one or more compounds and/or extracts that induce, promote and/or improve the production/release/delivery/secretion of hyaluronic acid and/or mucin from and/or in the cornea, and methods of treating the eye using the compositions.
Description
Cross Reference to Related Applications
This application claims benefit of the earlier filing date of U.S. provisional patent applications 62/937,458 and 62/937,473 filed on 19/11/2019, the entire contents of each such application being hereby incorporated by reference as if fully set forth herein.
Technical Field
The present invention relates to compositions comprising one or more compounds and/or extracts that induce, promote, and/or improve the production/release/delivery/secretion of mucins from and/or in the cornea, and methods of treating the eye using the compositions.
Background
"Dry eye" is a multifactorial disease of the ocular surface characterized by a loss of tear film homeostasis and is associated with ocular symptoms where tear film instability and high osmotic pressure, ocular surface inflammation and damage, and sensory nerve abnormalities play a causative role. "Craig, j.p. et al TFOS dess II definition and classification report Ocul Surf 2017; 15: 276-. Dry eye can be the result of a variety of underlying diseases, such as autoimmune diseases that damage the lacrimal glands (i.e., produce tears), such as rheumatoid arthritis, sjogren's syndrome, systemic lupus erythematosus, and systemic sclerosis and sarcoidosis. In eye surgery (such as
Surgery) may also cause dry eye. Dry eye is estimated to affect more than thirty million people in the united states.
Regardless of the underlying pathology, dry eye generally involves rapid breakdown of the pre-ocular tear film, resulting in dehydration of the exposed outer surface. Normal tear formation is required to keep the cornea and conjunctiva moist, and this in turn helps to prevent ulceration of both, as well as to maintain corneal transparency. In addition, tears facilitate movement of the eyelids on the surface of the eye (e.g., blinking) and removal of foreign matter from the eye. Tears typically also contain lysozyme, which can be used to prevent ocular infections. Dry eye can be associated with mild discomfort to severe pain in the eye. When dry eye occurs for a long period of time, it can cause blurred vision, a gritty and/or burning sensation, and itching. The condition may further lead to corneal ulceration and/or scarring if allowed to persist without treatment.
Dry eye symptoms include eye pain or fatigue, increased frequency of blinking, and ocular congestion. Furthermore, bacteria can enter through the scratch and cause infection, and if the scratch is deep enough, it can even affect a person's vision. In addition to eye fatigue, causes of dry eye include sjogren's syndrome, stevens-johnson syndrome, burns and eye injuries, as well as side effects of antihypertensive drugs, tranquilizers, eye drops for the treatment of glaucoma, and other such drugs.
Eye drops are an effective method for treating dry eye. Such eye drops typically include a dry eye therapeutic active-a common active in such eye drops is hyaluronic acid. Hyaluronic acid is a biologically derived macromolecular substance, has extremely high water retention and properties such as high viscoelasticity, good thickening properties, and good thread-forming ability, and has been used as a humectant in topical agents for treating various skin problems and the like. In the case where dry eye is caused by the sicca syndrome in which dryness is observed over the entire body, it is effective to apply an eye drop containing hyaluronic acid. However, when instilled as eye drops, hyaluronic acid has a relatively short residence time on the cornea, and therefore the effect of hyaluronic acid lasts only about 2 or 3 hours, which means that the patient has to administer the eye drops more frequently (e.g. 5 to 10 times per day).
Hyaluronic Acid (HA) is produced by corneal epithelial cells in the eye. Notably, studies found that hyaluronic acid concentrations in the cornea were significantly higher in younger populations than in older populations. (see Pacella, E., Paschella, F., De Paoli, G., et al. Glycosaminoglycerides in the human corn: image-related changes. Ophthalmol. eye Dis.7: 1-5,2015).
In addition, the tear film is the body's natural defense against dry eye. The tear film contains ocular mucin and is essential for maintaining homeostasis of the wet ocular surface. Mucins are produced by, among other things, corneal epithelial cells in the eye. Mucins are glycoproteins expressed by epithelial tissue of mucosal surfaces. They protect tissue by acting as antioxidants and providing lubrication. Mucin genes associated with tear film include MUC1, MUC2, MUC4, MUC5AC, MUC5B, MUC7, and MUC 16.
Mucins can also be used as antimicrobial agents, and both mucins and hyaluronic acid can be used for general wound healing and are essential for overall eye health maintenance.
Accordingly, there is a need for ophthalmic pharmaceutical compositions that will facilitate and/or improve the production and/or release of hyaluronic acid and/or mucin from and/or in the cornea.
The present inventors have found an extract or extract source of Pichia (Pichia) genus that can induce, promote and/or improve the production/release/delivery/secretion of hyaluronic acid and/or mucin from and/or in the cornea.
One aspect of the present invention therefore relates to a microemulsion composition comprising a safe and effective amount of one or more extracts or extract sources of pichia to induce, promote and/or improve the production/release/delivery/excretion of hyaluronic acid and/or mucin from and/or in the cornea.
Another aspect of the present invention relates to a method for inducing, promoting and/or improving the production/release/delivery/excretion of hyaluronic acid and/or mucin from and/or in the cornea, the method comprising the step of administering an ophthalmic microemulsion composition comprising a safe and effective amount of one or more pichia extracts or extract sources.
Another aspect of the present invention relates to a method for treating (e.g., reducing) and/or preventing dry eye or symptoms associated with dry eye, the method comprising the step of administering an ophthalmic microemulsion composition comprising one or more extracts or extract sources of the genus pichia.
Further aspects of the invention relate to methods for treating (e.g., reducing) and/or preventing dry eye or symptoms associated with dry eye, the methods comprising the step of administering an ophthalmic microemulsion composition comprising one or more extracts or extract sources of pichia.
Another aspect of the invention relates to methods of preventing and/or treating (e.g., reducing) ocular symptoms associated with dry eye and/or caused by reduced or low level production/release/delivery/excretion of hyaluronic acid and/or mucin from and/or in the cornea by administering an extract or extract sources comprising a safe and effective amount of one or more extracts of pichia.
One aspect of the invention relates to a composition comprising a safe and effective amount of one or more extracts or extract sources of pichia to induce, promote and/or improve the production/release/delivery/excretion of hyaluronic acid and/or mucin from and/or in the cornea, which composition can be administered to a patient having a concentration of MUC5AC in the tear fluid of less than 6 (or about 6) ng/mg protein, optionally 8 (or about 8) ng/mg protein, such that the concentration of MUC5AC in the tear fluid is raised to (or, brought to) a concentration equal to or greater than 8 (or about 8) ng/mg protein to 15 (or about 15) ng/mg protein, optionally 9 (or about 9) ng/mg protein to 12 (or about 12) ng/mg protein.
In certain embodiments, the above-described concentration of MUC5AC in tear fluid (i.e., equal to or greater than 8 (or about 8) ng/mg protein to 15 (or about 15) ng/mg protein, optionally 9 (or about 9) ng/mg protein to 12 (or about 12) ng/mg protein), produced by the compound and/or extract that induces, promotes and/or improves the production/release/delivery/excretion of hyaluronic acid and/or mucin from and/or in the cornea, is maintained for a period of time of up to at least about 2 hours, optionally about 4 hours, optionally about 6 hours, optionally about 8 hours, optionally about 10 hours, optionally about 12 hours, or optionally about 12 to about 24 hours.
The concentration of MUC5AC in tear fluid detailed above was determined using the Uchino method (described below in the definition).
A similar aspect of the invention relates to a method for inducing, promoting and/or improving the production/release/delivery/excretion of hyaluronic acid from and/or in the cornea, the method comprising the step of administering an ophthalmic composition comprising a safe and effective amount of one or more extracts or extract sources of the genus Pichia to induce, promote and/or improve the production/release/delivery/excretion of hyaluronic acid and/or mucin from and/or in the cornea, the composition being administrable to a patient having a hyaluronic acid concentration in tear fluid of less than 10 (or about 10) ng/mg protein, optionally less than 15 (or about 15) ng/mg protein, optionally less than 20 (or about 20) ng/mg protein or optionally less than 25 (or about 25) ng/mg protein, such that the concentration of hyaluronic acid in its tear fluid is raised to (or brought to) equal to or greater than 10 (or about 10) ng/mg protein, optionally equal to or greater than 15 (or about 15) ng/mg protein, optionally equal to or greater than 20 (or about 20) ng/mg protein, optionally equal to or greater than 25 (or about 25) ng/mg protein, optionally equal to or greater than 30 (or about 30) mg protein, optionally equal to or greater than 35 (or about 35) ng/mg protein, optionally equal to or greater than 40 (or about 40) ng/mg protein, or optionally equal to or greater than 45 (or about 45) ng/mg protein to 100 (or about 100) ng/mg protein, optionally 90 (or about 90) ng/mg protein, optionally 80 (or about 80) ng/mg protein, or, Optionally 70 (or about 70) ng/mg protein or optionally 60 (or about 60) ng/mg protein.
In certain embodiments, the above-described concentration of hyaluronic acid in a patient's tear produced by a compound and/or extract of the present invention is maintained for up to at least about 2 hours, optionally about 4 hours, optionally about 6 hours, optionally about 8 hours, optionally about 10 hours, optionally about 12 hours, or optionally about 12 to about 24 hours.
The Dreyfuss method (described in the definitions below) was used to determine the hyaluronic acid concentration detailed above.
Further aspects of the invention relate to methods of promoting healing or increasing the rate of healing of wounds in and/or on the eye of a patient (e.g., ocular wounds not associated with dry eye, post-operative surgery, or non-specific wounds) by administering a composition comprising a safe and effective amount of one or more extracts or extract sources of pichia to induce, promote, and/or improve production/release/delivery/excretion of hyaluronic acid and/or mucin from and/or in the cornea (i.e., increase production/release/delivery/excretion of hyaluronic acid or mucin from and/or in the cornea, in certain embodiments, over that typically produced by such patients without administration (or absence) of a composition comprising a safe and effective amount of one or more extracts or extract sources of pichia And/or the corresponding concentration level of mucin).
Yet another aspect of the present invention relates to a method of improving antimicrobial properties in the tear fluid (or tear film of the eye) of a patient by administering a composition comprising a safe and effective amount of one or more extracts or extract sources of pichia to induce, promote, and/or improve the production/release/delivery/excretion of hyaluronic acid and/or mucin from and/or in the cornea (i.e., increase the production/release/delivery/excretion of mucin from and/or in the cornea, in certain embodiments, over the concentration level of mucin that would normally be produced by such a patient in the absence of administration (or absence) of a composition comprising a safe and effective amount of one or more extracts or extract sources of pichia).
Disclosure of Invention
The present invention relates to a microemulsion composition for treating the eye, the microemulsion composition comprising:
i) one or more extracts or extract sources of pichia; and
ii) an ophthalmically acceptable carrier
WhereinThe microemulsion droplets or particles have a particle size of less than
Is measured.
The present invention relates to a method for producing/releasing/delivering/excreting mucin from and/or in the cornea, the method comprising the steps of: (optionally, in patients requiring such production/release/delivery/secretion of mucins) administering a composition, in certain embodiments, an ophthalmic microemulsion composition, comprising:
i) one or more extracts or extract sources of pichia;
ii) optionally, a safe and effective amount of a penetration enhancer; and
iii) optionally, an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
The present invention relates to a method for preventing or treating symptoms associated with dry eye, the method comprising the step of topically administering (optionally in a patient in need of such prevention or treatment) a microemulsion composition comprising:
i) one or more extracts or extract sources of pichia;
ii) one or more demulcents or soothing agents;
iii) optionally, a safe and effective amount of a penetration enhancer; and
iv) optionally, an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
The present invention relates to a method for maintaining the concentration of MU5AC in tear fluid in the range of equal to or greater than 8 ng to 15 ng/mg protein, comprising the step of administering a microemulsion composition (optionally in a patient in need of such maintenance) comprising:
i) one or more extracts or extract sources of pichia;
ii) optionally, a safe and effective amount of a penetration enhancer; and
iii) optionally, an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
The present invention relates to a method for treating a patient suffering from symptoms of reduced or low level production/release/delivery/excretion of mucin from and/or in the cornea, the method comprising the step of topically administering to the eye of the patient a microemulsion composition comprising:
i) one or more extracts or extract sources of pichia;
ii) optionally, a safe and effective amount of a penetration enhancer; and
iii) optionally, an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
The present invention relates to a method for preventing or treating symptoms associated with dry eye, the method comprising the step of topically administering to a patient (optionally, in a patient in need of such prevention of microemulsion or reduction of dry eye symptoms) a microemulsion composition comprising:
i) one or more extracts or extract sources of pichia;
ii) optionally, a safe and effective amount of a penetration enhancer; and
iii) optionally, an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
The present invention relates to methods for promoting healing or increasing the rate of wound healing in and/or on the eye (optionally, in a patient in need of such eye wound healing) by administering a composition comprising the step of administering a microemulsion composition (i.e., increasing production/release/delivery/excretion of mucin and/or hyaluronic acid from and/or in the cornea, in certain embodiments, above the concentration level of mucin produced by such a patient without administration (or absence) of a microemulsion composition comprising a safe and effective amount of one or more extracts or extract sources of pichia), the microemulsion composition comprising:
i) one or more extracts or extract sources of pichia; and
ii) optionally, an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
The present invention relates to methods for improving antimicrobial properties in a tear fluid of a patient (or tear film of the eye) (optionally, in a patient in need of such antimicrobial properties), comprising the step of administering a microemulsion composition (i.e., increasing production/release/delivery/excretion of mucin and/or hyaluronic acid from and/or in the cornea, in certain embodiments, over the concentration level of mucin produced by such a patient without administering (or in the absence of) a microemulsion composition comprising a safe and effective amount of one or more extracts or extract sources of pichia) comprising:
i) one or more extracts or extract sources of pichia;
ii) optionally, a safe and effective amount of a penetration enhancer; and
iii) optionally, an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
Drawings
Fig. 1 depicts a bar graph showing the increase in MUC4 expression in corneal epithelial cells after Pichia anomala (Pichia anomala) extract was added to growth medium containing corneal epithelial cells.
Fig. 2 depicts a bar graph showing the increase of mucin-1 secretion in corneal epithelial cells after pichia anomala extract was added to growth media containing corneal epithelial cells.
Fig. 3 depicts a bar graph showing increased mucin-1 production in corneal tissue cells following topical application of pichia anomala extract.
Fig. 4 depicts a bar graph showing increased HA production in corneal epithelial cells after topical administration of pichia anomala extract at 24 and 48 hours.
Fig. 5 depicts a bar graph showing a statistically significant increase in HA production in corneal epithelial cells 48 hours after placing the corneal epithelial cells in growth medium comprising pichia anomala extract.
Detailed Description
It is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following specific embodiments are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
The compositions of the present invention may comprise, consist of, or consist essentially of the elements, steps, and limitations described herein, as well as any of the additional or optional ingredients, components, or limitations described herein.
As used herein, the term "comprising (and grammatical variations thereof)" is used in an inclusive sense of "having" or "including" and not in an exclusive sense of "including only". As used herein, the terms "a" and "an" and "the" should be understood to encompass the plural as well as the singular.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety to the extent not inconsistent with this specification. As used herein, all percentages are by weight of the total composition, unless otherwise specified.
As used herein, the term "cornea" or "corneal" is, includes and/or relates to the transparent anterior portion of an eye covering the iris, pupil and anterior chamber, the layers of which transparent anterior portion include the corneal epithelial layer (including corneal epithelial cells), bowman's layer (also known as the anterior limiting membrane), corneal stroma (also the proper stroma), the posterior elastic layer (also the posterior limiting membrane) and the corneal endothelium (a simple squamous or low cubic monolayer of mitochondria-rich cells, about 5 μm thick).
The function of each layer is as follows:
epithelial provision:
providing a barrier to chemicals and water;
providing a barrier to microorganisms;
providing a smooth optical surface as an inner portion of the tear film-cornea interface, thereby contributing to the refractive power of the eye; and
accommodating langerhans cells that perform important immune functions.
A Bowman layer:
help to maintain the shape of the cornea.
Corneal stroma:
provide mechanical strength to the cornea;
provide transparency of the cornea; and
as a refractive lens.
Descemet's membrane:
used as a resting layer for endothelial cells.
Corneal endothelium:
corneal clarity is maintained by removing water from the corneal stroma.
The corneal epithelial layer is fairly uniformly composed of 5 to 7 layers of cells. The corneal epithelium is about 50 μ thick. The epithelium is uniform to provide a smooth, regular surface and is composed of non-keratinized stratified squamous epithelium. Without being limited by theory, it is believed that in the case of hyaluronic acid production, the corneal epithelial layer also comprises tight junction structures (i.e., those structures [ e.g., membranes or membrane barriers ] that generally inhibit chemical penetration into tissues) that can impede or act as barriers to diffusion of one or more extracts or extract sources of pichia, reducing diffusion of one or more extracts or extract sources of pichia through the corneal epithelium and into corneal tissue, thereby reducing the concentration levels of extracts that can accumulate within corneal tissue and contact the cellular portion of such tissues responsible for hyaluronic acid production.
As used herein, the phrase "reduced or low level of production/release/delivery/excretion of hyaluronic acid from and/or in the cornea" refers to hyaluronic acid concentrations less than that in normal (i.e., non-diseased) human tears, or in certain embodiments less than 25 (or about 25) nanograms per milligram of protein, as determined using the methods described in Dreyfuss JL, regateri CV, Coelho B et al. Altered hyaluronic acid content in tears of adenoviral conjunctivitis patients. An Acad Bras Cienc.2015; 87(1) 455-462 the method (Dreyfuss method) is reproduced as follows:
sample Collection
To collect tears, a Schirmer test strip was placed under the temporal eyelid of each eye for 5 minutes without any local anesthetic. The strips were dried at room temperature and stored at-20 ℃ until analysis.
Tear sample preparation
Tear compounds were eluted from Schirmer strips with 100 μ L of distilled water and hyaluronic acid and protein content analysis was performed.
Determination of hyaluronic acid
The hyaluronic acid content in tears was determined by non-isotopic fluorescence analysis (see Martins Jr, Passerotti CC, macel RM, Sampaio Lo, Dietrich CP and Nader hb.2003). A novel, non-competitive, fluorescence method for the determination of hyaluronic acid in the serum of normal and cirrhosis patients. (Anal Biochem 319:65-72.) the eluted tears and a standard concentration of hyaluronic acid (Sigma, st. louis, MO) were added to 96-well plates (fluoronuc Maxisorp-microorganisms, Roskilde, Denmark) previously coated with hyaluronic acid binding protein. The plates were then incubated with biotinylated hyaluronic acid binding protein and europium-labeled streptavidin (Amersham, Piscataway, N.J.) in that order. Thereafter, europium remaining in the solid phase was released by enhancing the solution, and fluorescence was measured using a time-resolved fluorometer (Perkin-Elmer Life Sciences-Wallac Oy, Turku, Finland). Data (counts/sec) were processed automatically using the MultiCalc software program (Perkin-Elmer Life sciences-Wallac Oy), with values expressed as ng/mg protein.
Protein analysis
Total tear protein concentration was determined using a colorimetric assay kit (protein assay kit from Bio-Rad, Hercules, Calif.) according to the manufacturer's instructions. Protein mass spectra were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) as previously described (see Laemmli UK.1970.Cleavage of structural proteins along the assembly of the head of bacteria T4.Nature 227: 680. 685.). Briefly, 10 μ g of protein from a tear fluid sample was applied to a 3% -20% linear gradient polyacrylamide gel under reducing conditions. After electrophoresis, the gel was stained with Coomassie Brilliant blue (Bio-Rad, Hercules, Calif.). Each protein band was quantified by densitometry using Mac's software ImageJ version 10.2(u.s. national Institutes of Health, Bethesda, Maryland, USA). The results are expressed in arbitrary optical density units (ADU).
As used herein, the phrase "reduced or low level of production/release/delivery/excretion of mucin from and/or in the cornea" refers to a concentration of MUC5AC that is less than the concentration of MUC5AC in normal human (i.e., non-diseased) tears, or in certain embodiments less than 6 nanograms per milligram of protein, optionally less than 8 nanograms per milligram of protein, as determined using the methods described in Uchino Y, Uchino M, Yokoi N, et al. Change in office tear mucin 5AC using visual display terminal: the Osaka study, jama ophthalmol, n 2014; 132(8):985-992. The method (Uchino method) is reproduced as follows:
concentration of MUC5AC in lacrimal fluid
The concentration of mucin MUC5AC secreted in tears was determined by enzyme-linked immunoassay (E90756 HU; USCN Life Science). (see Maker AV, Katabi N, Gonen M, et al. functional cell fluid and serum levels differential in intracellular plasma and serum levels of microorganisms of the company, Ann Surg Oncol.2011; 18(1): 199. sub.206.) all samples were analyzed according to the manufacturer's instructions. The absorbance was measured at 450nm and the standard solution in the kit was recombinant human MUC5 AC. A Protein Assay Kit (BCA Protein Assay Kit; Pierce) was used to determine the Protein concentration in tear samples. The MUC5AC concentration was normalized to the tear protein content and expressed as MUC5AC protein (nanograms)/total tear protein (milligrams).
As used herein, a composition that is "substantially free" of an ingredient refers to a composition having about 2% by weight or less of the ingredient (based on the total weight of the composition). Preferably, a composition that is substantially free of an ingredient has about 1% by weight or less of the ingredient (based on the total weight of the composition), more preferably about 0.5% by weight or less, more preferably about 0.1% by weight or less, more preferably about 0.05% by weight or less, more preferably about 0.01% by weight or less of the ingredient. In certain more preferred embodiments, a composition that is substantially free of an ingredient is free of that ingredient, that is, the composition is completely free of that ingredient.
As used herein, "microemulsion" refers to an emulsion having one or more of the following characteristics: i) the microemulsion forms spontaneously or substantially spontaneously when its components are brought into contact, i.e., without substantial energy supply, for example in the absence of heating or without the use of high shear equipment or other substantial agitation; ii) the microemulsion exhibits thermodynamic stabilitySex; iii) the microemulsion is single phase; iv) the microemulsion is substantially opaque, i.e., transparent or opalescent when viewed through the optical microscopic means; and/or v) in its undisturbed state, the microemulsion is optically isotropic, but anisotropic structures can be observed using, for example, x-ray techniques. The particles of the microemulsion may be spherical, however other structures are also feasible, for example liquid crystals with lamellar, hexagonal or isotropic symmetry. Generally, microemulsions comprise a maximum dimension (e.g., diameter) of less than
Preferably less than
Preferably less than
But greater than
Droplets or particles of (a). The definition of microemulsion includes Self Emulsifying Drug Delivery Systems (SEDDS). SEDDS is an isotropic mixture of oil, surfactant (with or without co-surfactant) and co-solvent, which spontaneously emulsifies on exposure to aqueous media under mild agitation. The SEDDS can be used to improve the bioavailability of poorly soluble drugs via oral administration. The addition of a co-solvent facilitates the formation of a self-emulsifying system, since the co-solvent significantly reduces the interfacial tension. In doing so, the co-solvent produces a fluid interfacial film with sufficient flexibility to occupy the different curvatures required to form a microemulsion over a wide range of compositions. Further details regarding SEDDS may be found in U.S. patent publication US2018/0036233A1 to Shabaik et al, which is incorporated herein by reference in its entirety.
As used herein, "ophthalmically acceptable" means that the ingredients described by the term are suitable for use in contact with tissue (e.g., soft eye tissue or periorbital skin tissue) without causing undue toxicity, incompatibility, instability, irritation, allergic response, and the like. As will be appreciated by those skilled in the art, cosmetically/dermatologically acceptable salts are acidic/anionic or basic/cationic salts.
As used herein, the term "safe and effective amount" refers to an amount of the disclosed extract, compound, or composition that is up to sufficient to induce, promote, and/or improve the production/release/delivery/secretion of hyaluronic acid and/or mucin from and/or in the cornea, but is as little as sufficient to avoid serious side effects. The safe and effective amount of the compound, extract or composition will vary with such factors as the age, health and environmental exposure of the end user, the duration and nature of the treatment, the particular extract, ingredient or composition employed, and the particular ophthalmically acceptable carrier employed.
In certain embodiments, the invention as disclosed herein may be practiced in the absence of any compound or element (or group of compounds or elements) not specifically disclosed herein.
Generally, IUPAC nomenclature is used herein and is defined in accordance with the following terms.
The term "C1-8 alkyl" whether used alone or as part of a substituent group, refers to a saturated aliphatic branched or straight chain monovalent hydrocarbon radical having from 1 to 8 carbon atoms. For example, "C1-8 alkyl" specifically includes the groups methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, t-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexyl, 3-hexyl, 1-heptyl, 2-heptyl, 3-heptyl, 1-octyl, 2-octyl, 3-octyl, and the like. The term may also refer to the corresponding alkanediyl. Alkyl and alkanediyl groups may be attached to the core molecule via a terminal carbon atom or via a carbon atom in the chain. Similarly, any number of substituent variables may be attached to an alkyl or alkanediyl group as the available valences permit.
The term "C1-4Alkyl "whether used alone or as part of a substituent group, refers to a saturated aliphatic branched or straight chain monovalent hydrocarbon radical or alkanediyl linking group having the specified number of carbon atoms, wherein the group is derived by removal of one hydrogen atom from a carbon atom, and an alkanediyl groupRadical linking groups are derived by removing one hydrogen atom from each of two carbon atoms in the chain. The term "C1-4Alkyl "refers to a straight or branched chain arrangement of groups having 1 to 4 carbon atoms. For example, "C1-4Alkyl "specifically includes the groups methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, t-butyl, 1-butyl, and the like. Alkyl and alkanediyl groups may be attached to the core molecule via a terminal carbon atom or via a carbon atom in the chain. Similarly, any number of substituent variables may be attached to an alkyl or alkanediyl group as the available valences permit.
The term "C2-4Alkenyl "means alkenyl having 2 to 4 carbon atoms. For example, specifically included are the groups vinyl, propenyl, allyl (2-propenyl), butenyl, and the like. As described above, alkenyl groups may be similarly attached to the core molecule and further substituted as indicated.
The term "halogen" by itself or in combination with other terms refers to a halogen atom, such as fluorine, chlorine, bromine, or iodine.
The term "substituted" means that one or more hydrogen atoms on the core molecule have been replaced with a substituent that is available in a valence-permitting amount. The substitution is not limited to the core molecule, but may be carried out on a substituent such that the group becomes a linking group.
The term "independently selected" refers to two or more substituents that may be selected from a variable group of substituents, wherein the selected substituents may be the same or different.
The term "dependently selected" means that one or more substituent variables designated in the indicated combination for substitution in the core molecule (e.g., variables relating to the group of substituents appearing in a tabular listing of compounds).
Acceptable salts from inorganic bases include, for example, sodium or potassium salts and the like. Acceptable salts from organic bases include, for example, salts with primary, secondary, tertiary amines, and the like.
Compounds and/or extracts that induce, promote and/or improve the production/release/delivery/secretion of hyaluronic acid and/or mucin in the cornea.
The invention includes inducing, promoting and/or ameliorating hyaluronic acid and/or mucin from and/or in the cornea One or more compounds and/or extracts of (a) production/release/delivery/secretion。
In certain embodiments, the compound and/or extract that induces, promotes and/or improves the production/release/delivery/secretion of hyaluronic acid and/or mucin from and/or in the cornea is or comprises an extract or extract source of pichia.
Pichia pastoris is a genus of Saccharomyces in the family Saccharomyces. Over 100 species are known in this genus. Suitable bacterial species for use in the compositions of the present invention include (selected from or selected from the group consisting of: pichia anomala (Pichia anomala), Pichia guilliermondii (Pichia guillierirmondii), Pichia norway (Pichia norvegensis), Pichia ohmerii (Pichia ohmeri). Pichia anomala (formerly known as Hansenula anomala) can be present in raw milk and cheese. The extract of yeast of the genus pichia is rich in mannan (polysaccharide composed of mannose monomers). The extract or source of extract of the genus pichia can be isolated from the fruit or other aerial parts of the plant. Any ophthalmically acceptable extract of pichia can be used. Extracts or mixtures of extract sources from the above mentioned species of the genus pichia may also be used.
In certain embodiments, the extract or source of extract from pichia used in the present invention is an extract of pichia anomala. The extract of Pichia can be isolated from the fruit or other aerial parts of the plant. In certain embodiments, a suitable pichia anomala extract is produced by a pichia anomala strain present on the fruit or leaf of a kiwi plant. In another embodiment, the Pichia anomala extract can be PRO-LIPIISKIN or
Commercially available from Silab-France, where the extract was produced from a Pichia anomala strain present on sugarcane. Preferred for use herein areAn extract of pichia pastoris, characterized by having:
-a solids content between 26g/l and 40g/l,
-a pH between 6 and 7,
-a protein content between 2g/l and 170g/l, and
sugar content ranging between 18g/l and 30g/l (mannose curve)
(wherein the characterization belongs to PRO-LIPIISKIN and Hyalurodine (Silab-France)). Hyalurodine is the Pichia anomala extract used in the examples (below). In one embodiment, pichia anomala extract is obtained according to the following procedure as described in FR2897266 and FR2938768, both of which are incorporated herein by reference.
In certain embodiments, the extraction methods described below remove a majority of the protein from the pichia extract and concentrate the active in the form of mannan. The method comprises at least one step of enzymatic hydrolysis of the protein to obtain peptides and small proteins, and in certain embodiments, further comprises another step of removing these small peptides and proteins by filtration based on the selection of the size of such molecules.
In certain embodiments, the extract of pichia, including pichia anomala extract, is obtained by an extraction process involving one or more hydrolases to sequentially or simultaneously hydrolyze proteins in pichia.
In certain embodiments, enzymatic hydrolysis is used to break down the proteins in the extract of pichia into protein fractions having a weight average molecular weight of less than 5000 Da. Suitable hydrolases include, but are not limited to, at least one peptidase selected from papain, trypsin, chymotrypsin, subtilisin, pepsin, thermolysin, pronase, zinc metallo-endopeptidase (flavostatin), enterokinase, factor Xa protease, Turin, bromelain, proteinase K, genease I, thermolysin, carboxypeptidase a, carboxypeptidase B, collagenase, or mixtures thereof, in certain embodiments.
In certain embodiments, the enzymes used to obtain the pichia extract are inactivated prior to separating the resulting soluble and insoluble phases.
In one embodiment, the pichia anomala extract is characterized by having:
-a solids content of between 5g/l and 300g/l,
-a pH between 4 and 9,
-a protein content of between 2 and 10g/l, preferably between 3 and 9g/l, and
sugar content ranging between 1g/l and 100g/l (mannose curve)
In certain embodiments, the pichia extract comprises a mannan content of greater than or equal to 30% by weight of the total dry pichia extract, or optionally comprises a mannan content of at least 50% by weight of the total dry pichia extract.
In certain embodiments, the pichia extract-containing phase is dried (and the solids content is measured) by passing the phase through an oven at 105 ℃ (or about 105 ℃) in the presence of sand until a constant weight is obtained/observed.
In certain embodiments, the solid (or dry matter) content of the dried Pichia extract is between 10g/l and 200g/l, or optionally between 26g/l and 40 g/l.
In certain embodiments, the pH measured potentiometrically at room temperature (25 ℃) results in a value of between 4.5 and 8.5, optionally between 6.0 and 7.0.
For determination of total sugar content, the DUBOIS method may be used. In the presence of concentrated sulfuric acid and phenol, reducing sugar produces orange yellow compound. From the standard range (preferably using a mannose measurement curve), the total sugar content of the sample can be determined. In certain embodiments, the dry Pichia extract has a total sugar content of between 7g/l and 145g/l, or optionally between 18g/l and 29 g/l. In certain embodiments, the dried pichia extract comprises at least 30 wt.% total sugars, optionally at least 50 wt.% of the dried pichia extract, compared to the total solids weight of the dried pichia extract.
In certain embodiments, the carbohydrate fraction of the dried pichia extract consists of mannose and glucose in the form of (or substantially in the form of) oligosaccharides and polysaccharides having a weight average molecular weight of from about 180Da to about 800,000Da, optionally from about 5000Da to about 515,000Da, optionally from about 6000Da to about 270,000 Da. In certain embodiments, at least 70% (or about 70%), optionally at least 75% (or about 75%), at least 80% (or about 80%), optionally at least 85% (or about 85%), at least 90% (or about 90%), optionally at least 95% (or about 95%) or 100% (or about 100%) of the oligosaccharides and polysaccharides in the dried pichia extract fall within the above weight average molecular weight ranges.
The determination of the protein content is obtained by a Kjeldahl method. In certain embodiments, the protein content of the dried Pichia extract is between 4g/l and 90g/l, or optionally between 12g/l and 18 g/l. The dried pichia extract comprises less than 45% protein, or optionally less than 30% total solids in the dried pichia extract.
In certain embodiments, the dried pichia extract comprises mannan, mannose polymerized in the form of oligosaccharides and polysaccharides having a weight average molecular weight of from about 180Da to about 800,000Da, optionally from about 5000Da to about 515,000Da, optionally from about 6000Da to about 270,000 Da. In certain embodiments, at least 70% (or about 70%), optionally at least 75% (or about 75%), at least 80% (or about 80%), optionally at least 85% (or about 85%), at least 90% (or about 90%), optionally at least 95% (or about 95%) or 100% (or about 100%) of the oligosaccharides and polysaccharides in the dried pichia extract fall within the above weight average molecular weight ranges.
In certain embodiments, the extraction process comprises a step of removing (e.g., by filtration) proteins having a weight average molecular weight of less than 5000Da after the step of enzymatic hydrolysis of the proteins. Thus, the Pichia extract is free or substantially free of proteins and/or peptides having a weight average molecular weight of less than 5000 Da.
In certain embodiments, the above extraction methods may include a step of deodorizing, bleaching and/or stabilizing the pichia extract prior to filtration. The filtration may be as follows: -pressure filtration and-sterile filtration.
In certain embodiments, the extract used is of the species pichia anomala. Specific non-limiting examples of production methods are described below.
-culturing the extract (or yeast) of Pichia anomala in a medium suitable for its development and then centrifuging to recover the biomass,
-then grinding the biomass in a ball mill. The ground material was then resuspended in water at a concentration of 50 g/l, after which it was enzymatically hydrolyzed in alkaline medium at 30 ℃ for 6 hours,
after hydrolysis, the product is centrifuged and filtered before sterilization,
-obtaining a hydrolysate comprising at least 30% mannan relative to the total weight of solids and/or obtaining a protein of a specific weight average molecular weight by successive filtration on filters of different sizes. (the hydrolysate obtained was in the form of a light yellow clear liquid aqueous solution.) in certain embodiments, the pichia anomala extract was obtained according to the following manufacturing example:
1. pichia anomala extract a:
I. extracting a pichia anomala extract A:
the preparation method of the pichia anomala extract A comprises the following steps:
-culturing Pichia anomala of the genus Saccharomyces in a medium suitable for its development,
-centrifuging the recovered biomass to recover the biomass,
-the dissolution of the biomass,
-enzymatic hydrolysis at alkaline pH,
-separation of the soluble and insoluble phases,
-a heat treatment,
-filtration, and
-sterile filtration.
Characterization of pichia anomala extract a:
the pichia anomala extract a obtained above was characterized in that:
-a solids content of between 48g/l and 84g/l,
-a pH between 4 and 9,
-a protein content of between 19g/l and 48g/l, and
-a total sugar content of between 10g/l and 42 g/l.
2. Pichia anomala extract B
I. Extracting the abnormal pichia pastoris extract B:
the preparation method of the pichia anomala extract B comprises the following steps:
-culturing Pichia anomala of the genus Saccharomyces in a medium suitable for its development,
-centrifuging the recovered biomass to recover the biomass,
-the dissolution of the biomass,
-enzymatic hydrolysis at an acidic pH,
-separation of the soluble and insoluble phases,
-a heat treatment,
-filtration, and
-sterile filtration.
Characterization of pichia anomala extract B:
the pichia anomala extract B obtained above was characterized in that:
-a solids content of between 58g/l and 95g/l,
-a pH between 4 and 9,
-a protein content of between 23g/l and 54g/l, and
-a total sugar content between 12g/l and 32 g/l.
3. Pichia anomala extract C
I. Extracting the abnormal pichia pastoris extract C:
the preparation method of the pichia anomala extract C comprises the following steps:
-culturing Pichia anomala of the genus Saccharomyces in a medium suitable for its development,
-centrifuging the recovered biomass to recover the biomass,
-the dissolution of the biomass,
continuous enzymatic hydrolysis in alkaline medium,
-separation of the soluble and insoluble phases,
-a heat treatment,
-filtration, and
-sterile filtration.
Characterization of pichia anomala extract C:
the pichia anomala extract C obtained above was characterized in that:
-a solids content of between 91g/l and 195g/l,
-a pH between 4 and 9,
-a protein content of between 36 and 111g/l, and
-a total sugar content between 18 and 65 g/l.
4. Pichia anomala extract D
I. Extracting a pichia anomala extract D:
the preparation method of the Pichia anomala extract D comprises the following steps:
-culturing Pichia anomala of the genus Saccharomyces in a medium suitable for its development,
-centrifuging the recovered biomass to recover the biomass,
-the dissolution of the biomass,
-hydrolysis simultaneously with at least two enzymes at acidic pH,
-separation of the soluble and insoluble phases,
-a heat treatment,
-filtration, and
-sterile filtration.
Characterization of pichia anomala extract D:
the pichia anomala extract D obtained above was characterized in that:
-a solids content of between 5g/l and 53g/l,
-a pH between 4 and 9,
-a protein content of between 2g/l and 30g/l, and
-a total sugar content of between 1g/l and 18 g/l.
5. Pichia anomala extract E
I. Extracting a pichia anomala extract E:
the preparation method of the Pichia anomala extract E comprises the following steps:
-culturing Pichia anomala of the genus Saccharomyces in a medium suitable for its development,
-centrifuging the recovered biomass to recover the biomass,
-dissolution of biomass in an aqueous glycol environment,
-hydrolysis simultaneously with at least two enzymes at acidic pH,
-separation of the soluble and insoluble phases,
-a heat treatment,
-filtration, and
-sterile filtration.
Characterization of pichia anomala extract E:
the pichia anomala extract E obtained above was characterized in that:
-a solids content between 172g/l and 300g/l,
-a pH between 4 and 9,
-a protein content of between 69g/l and 170g/l, and
-a total sugar content of between 34g/l and 100 g/l.
Preferably, the pichia anomala extract is obtained using the method for obtaining pichia anomala extract D as described above.
In certain embodiments, the pichia extract or extract source comprises oligosaccharides and polysaccharides having an average degree of polymerization of DP 1 to DP 4444, optionally DP 30 to DP 2860, optionally DP 35 to DP 1500. In certain embodiments, at least 70% (or about 70%), optionally at least 75% (or about 75%), at least 80% (or about 80%), optionally at least 85% (or about 85%), at least 90% (or about 90%), optionally at least 95% (or about 95%) or 100% (or about 100%) of the oligosaccharides and polysaccharides in the dried pichia extract fall within the above-described average dp range.
In certain embodiments, the extract or extract source of pichia is present in the compositions of the present invention to provide at least 0.3mg/ml (or about 0.3mg/ml), optionally at least 0.5mg/ml (or about 0.5mg/ml), optionally at least 1mg/ml (or about 1mg/ml), optionally at least 1.5mg/ml (or about 1.5mg/ml), optionally at least 2mg/ml (or about 2mg/ml), optionally at least 2.5mg/ml (or about 2.5mg/ml), optionally at least 3mg/ml (or about 3mg/ml), optionally at least 3.5mg/ml (or about 3.5mg/ml) when in or contacting corneal tissue cells (i.e., an intracorneal fluid layer) of the user after topical administration, optionally at least 4mg/ml (or about 4mg/ml), optionally at least 4.5mg/ml (or about 4.5mg/ml), optionally at least 5mg/ml (or about 5mg/ml), or at least 5.5mg/ml (or about 5.5mg/ml), optionally at least 6mg/ml (or about 6mg/ml), or optionally at least 6.5mg/ml (or about 6.5mg/ml), optionally at least 7mg/ml (or about 7mg/ml), optionally at least 7.5mg/ml (or about 7.5mg/ml), optionally at least 8mg/ml (or about 8mg/ml), optionally at least 8.5mg/ml (or about 8.5mg/ml), optionally at least 9mg/ml (or about 9mg/ml), optionally at least 8.5mg/ml (or about 8.5mg/ml), optionally at least 9mg/ml (or about 9mg/ml), optionally at least 9.5mg/ml (or about 9.5mg/ml), or optionally at least 10mg/ml (or about 10mg/ml) to 100mg/ml (or about 100mg/ml), optionally to 95mg/ml (or about 95mg/ml), optionally to 90mg/ml (or about 90mg/ml), optionally to 85mg/ml (or about 85mg/ml), optionally to 80mg/ml (or about 80mg/ml), optionally to 75mg/ml (or about 75mg/ml), optionally to 70mg/ml (or about 70mg/ml), optionally to 65mg/ml (or about 65mg/ml), optionally to 60mg/ml (or about 60mg/ml), optionally to 55mg/ml (or about 55mg/ml), optionally to a concentration of 50mg/ml (or about 50mg/ml), optionally to 45mg/ml (or about 45mg/ml), optionally to 40mg/ml (or about 40mg/ml), optionally to 35mg/ml (or about 35mg/ml), optionally to 30mg/ml (or about 30mg/ml), optionally to 25mg/ml (or about 25mg/ml), optionally to 20mg/ml (or about 20mg/ml), or optionally to 15mg/ml (or about 15mg/ml) of the Pichia pastoris extract.
In certain embodiments, the extract or extract source of pichia is from 0.01% (or about 0.01%), optionally from 0.05% (or about 0.05%), optionally from 0.1% (or about 0.1%), optionally from 0.5% (or about 0.5%), optionally from 1% (or about 1%), optionally from 1.5% (or about 1.5%), optionally from 2% (or about 2%), optionally from 2.5% (or about 2.5%), optionally from 3% (or about 3%), optionally from 3.5%, (or about 3.5%), optionally from 4% (or about 4%), optionally from 4.5% (or about 4.5%), optionally from 5% (or about 5%), optionally from 5.5% (or about 5.5%), optionally from 6% (or about 6%), optionally from 6.5% (or about 6.5%), optionally from 7% (or about 7.5%), optionally from 7.5%, optionally from 3.5%, or about 3.5%), based on the weight of the total composition, optionally from 8% (or about 8%), optionally from 8.5% (or about 8.5%), optionally from 9% (or about 9%), optionally from 9.5% (or about 9.5%), optionally from 10% (or about 10%), optionally from 10.5% (or about 10.5%), optionally from 11% (or about 11%), optionally from 11.5% (or about 11.5%), optionally from 12% (or about 12%), optionally from 12.5% (or about 12.5%), optionally from 13% (or about 13%), optionally from 13.5% (or about 13.5%), optionally from 14% (or about 14%), optionally from 14.5% (or about 14.5%), optionally from 15% (or about 15%), optionally from 15.5% (or about 15.5%), optionally from 16% (or about 16%), optionally from 16.5% (or about 16.5%), optionally from 17% (or about 17%), optionally from 17.5% (or about 17.5%), optionally from 18% (or about 18%), optionally from 18.5% (or about 18.5%), optionally from 19% (or about 19%), optionally from 19.5% (or about 19.5%), optionally from 20% (or about 20%), optionally from 20.5% (or about 20.5%) to 30% (or about 30%), optionally to 35% (or about 35%), optionally to 40% (or about 40%), optionally to 45% (or about 45%), optionally to 50% (or about 50%), optionally to 55% (or about 55%), optionally to 60% (or about 60%), optionally to 65% (or about 65%), optionally to 70% (or about 70%), optionally to 75% (or about 75%), optionally to 80% (or about 80%), optionally to 85% (or about 85%), optionally to 90% (or about 90%), optionally to 95% (or about 95%), or optionally to 100% (or about 100%) concentration in the compositions of the present invention.
Penetration enhancer
In certain embodiments, the compositions of the present invention optionally comprise a penetration enhancer.
Suitable penetration enhancers include (selected from or selected from the group consisting of: surfactants such as saponin, polyoxyethylene ethers of fatty acids (such as polyoxyethylene 4-, 9-, 10-, and 23-lauryl ether, polyoxyethylene 10-and 20-cetyl ether, polyoxyethylene 10-and 20-stearyl ether), sorbitan monooleate, sorbitan monolaurate, polyoxyethylene sorbitan (such as polyoxyethylene sorbitan monolaurate), quaternary ammonium decahydrocarbide, and dodecyltrimethylammonium bromide; chelating agents such as natural polyacids (e.g., citric acid), phosphates (e.g., disodium pyrophosphate), phosphonates, bisphosphonates (e.g., hydroxyethylidene diphosphonic acid), aminocarboxylic acids (e.g., ethylenediaminetetraacetic acid (EDTA) and disodium edetate) and ethylenediamine-N, N' -disuccinic acid (EDDS)); bile salts and acids such as cholic acid, deoxycholic acid, glycocholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium cholate, sodium glycocholate, sodium deoxycholate, sodium taurodeoxycholate, chenodeoxycholic acid, and ursodeoxycholic acid; fusidic acid derivatives, glycyrrhizic acid and ammonium glycyrrhizinate, and saponin EDTA, fusidic acid, polyoxyethylene 9-lauryl ether, polyoxyethylene 20-stearyl ether, glycocholate or mixtures of any of the above.
The concentration of the permeation enhancer applied should be the minimum amount necessary to increase absorption of the compound and/or extract through the mucus or other barrier membrane of the eye. Generally, ranges from 0.01% (or about 0.01%), optionally from 0.05% (or about 0.05%), optionally from 0.1% (or about 0.1%), optionally from 0.15% (or about 0.15%), optionally from 0.2% (or about 0.2%), optionally from 0.25% (or about 0.25%) to 2% (or about 2%), optionally to 2.5% (or about 2.5%), optionally to 3% (or about 3%), optionally to 3.5%, (or about 3.5%), optionally to 4% (or about 4%), optionally to 4.5% (or about 4.5%), optionally to 5% (or about 5%), optionally to 5.5% (or about 5.5%), optionally to 6% (or about 6%), optionally to 6.5% (or about 6.5%), optionally to 7% (or about 7%), optionally to 7.5% (or about 7.5%), optionally to 8% (or about 8.5%), optionally to 8.5% (or about 8.5%), optionally to 9% (or about 9%), optionally to 9.5% (or about 9.5%), optionally to 10% (or about 10%), optionally to 10.5% (or about 10.5%), optionally to 11% (or about 11%), optionally to 11.5% (or about 11.5%), optionally to 12% (or about 12%), optionally to 12.5% (or about 12.5%), optionally to 13% (or about 13%), optionally to 13.5% (or about 13.5%), optionally to 14% (or about 14%), optionally to 14.5% (or about 14.5%), optionally to 15% (or about 15%), optionally to 15.5% (or about 15.5%), optionally to 16% (or about 16%), optionally to 16.5% (or about 16.5%), optionally to 17% (or about 17%), optionally to 17.5% (or about 17.5%), optionally to 18% (or about 18), optionally to 18.5% (or about 18.5%), optionally to 11%, optionally to 18.5%), optionally to 12%, optionally to 12.5%, optionally to 12%, optionally to 12.5%, or to 12%, optionally to 12., optionally, a concentration (w/v) of up to 19% (or about 19%), optionally up to 19.5% (or about 19.5%), optionally up to 20% (or about 20%) of the total composition may be used in the compositions of the invention.
Ophthalmologically acceptable carrier
The compositions of the present invention further comprise an aqueous solution, an oil-in-water emulsion, a water-in-oil emulsion carrier, an oil-in-water microemulsion, or a water-in-oil microemulsion carrier. The carrier is ophthalmically acceptable. Useful oil-in-water and water-in-oil carriers can be found in U.S. patent publication 20030165545a1 and U.S. patents 9480645, 8828412, and 8496976, each of which is incorporated herein by reference in its entirety.
In certain embodiments, the compositions of the present invention comprise an emulsion, optionally a self-emulsifying emulsion, comprising an oily component such as one or more oils, for example, but not limited to, mineral oil and/or one or more other conventional well-known and/or commercially available oils suitable for use in the present invention; a surfactant component comprising three or more surfactants; and an aqueous component comprising an aqueous phase. In addition, a variety of additional components may be included in the compositions of the present invention. The compositions of the present invention are substantially non-toxic and/or non-irritating and/or non-injurious to the eye and provide protective functions to cells and tissues of the eye.
One or more oils or oily substances are used to form the compositions of the present invention. Any suitable oil or oily substance or combination of oils or oily substances may be used, provided that such oil and/or oily substance is effective in the compositions of the invention and does not cause any significant or significant deleterious effect on the human or animal to which the composition is applied, or the contact lens being treated, or the wearing of the contact lens being treated, or the wearer of the contact lens being treated. The oily component may be, for example, but not limited to, higher fatty acid glycerides, such as castor oil, corn oil, sunflower oil, and the like, and mixtures thereof. The oily component may include one or more non-polar oils, such as mineral oil, silicone oil, and the like, and mixtures thereof.
The ophthalmically acceptable carrier (or composition of the present invention) may optionally comprise one or more additional excipients and/or one or more additional active ingredients. Examples of such optional components are described below.
Excipients commonly used in ophthalmic compositions include, but are not limited to, demulcents, tonicity agents, preservatives, chelating agents, buffering agents (other than and in addition to the organic acids of the present invention), and surfactants. Other excipients include solubilizers, stabilizers, comfort enhancers, polymers, emollients, pH adjusters (not and in addition to the organic acids of the present invention) and/or lubricants. Any of a variety of excipients may be used in the compositions of the present invention, including mixtures of water, water and water-miscible solvents, such as vegetable or mineral oils containing from 0.5% to 5% of a non-toxic water-soluble polymer, natural products such as agar and gum arabic, starch derivatives such as starch acetate and hydroxypropyl starch, and other synthetic products such as polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl methyl ether, polyethylene oxide, and preferably cross-linked polyacrylic acid and mixtures thereof.
Demulcents or soothing agents for use with embodiments of the present invention include, but are not limited to, cellulose derivatives (such as hydroxyethylcellulose, methylcellulose, hypromellose, or mixtures thereof), hyaluronic acid or salts thereof (such as sodium hyaluronate), tamarind seed extract, glycerin, polyvinylpyrrolidone, polyethylene oxide, polyethylene glycol, propylene glycol, and polyacrylic acid, and mixtures thereof. In certain embodiments, one or more of hyaluronic acid, propylene glycol, tamarind seed extract, glycerin, and/or polyethylene glycol 400 is a soothing or soothing agent. In certain embodiments, the soothing or soothing agent is selected from hyaluronic acid, tamarind seed extract, or mixtures thereof.
The compositions of the present invention are ophthalmically suitable for administration to the eye of a subject. The term "aqueous" generally refers to an aqueous formulation wherein the excipient is greater than about 50%, more preferably greater than about 75%, and specifically greater than about 90% water by weight. In certain embodiments, the compositions of the present invention are substantially free of compounds that irritate the eye. In certain embodiments, the compositions of the present invention are substantially free of free fatty acids and C1To C4An alcohol. In certain embodiments, the compositions of the present invention comprise less than 40% (or about 40%), optionally less than 35% (or about 35%), optionally less than 30% (or about 30%), optionally less than 25% (or about 25%), optionally less than 20% (or about 20%), optionally less than 15% (or about 15%), optionally less than 10% (or about 10%) or optionally less than 5% (or about 5%) non-alcohol, organic excipient or solvent by weight of the total composition. These droplets may be delivered in single dose ampoules, which are preferably sterile, so that no bacteriostatic component is required in the formulation. Alternatively, the droplets may be delivered in a multi-dose bottle which may preferably include means to extract any preservatives from the composition as it is delivered, such means being known in the art.
In certain embodiments, the compositions of the present invention are isotonic or slightly hypotonic in order to combat any hypertonicity of tears caused by evaporation and/or disease. This may require a tonicity agent to bring the osmolality of the formulation to a level of or near 210-320 millimoles per kilogram (mOsm/kg). The compositions of the present invention typically have an osmolarity in the range of 220-320mOsm/kg, or optionally in the range of 235-300 mOsm/kg. Ophthalmic compositions will generally be formulated as sterile aqueous solutions.
The degree of penetration of the compositions of the present invention may be adjusted with tonicity agents to a value compatible with the intended use of the composition. For example, the permeability of the composition can be adjusted to approximate the permeability of normal tears, which is equivalent to about 0.9 w/v% sodium chloride in water. Examples of suitable tonicity adjusting agents include, but are not limited to, sodium chloride, potassium chloride, calcium chloride, and magnesium chloride; dextrose; glycerol; propylene glycol; mannitol; sorbitol, and the like, and mixtures thereof. In one embodiment, a combination of sodium chloride and potassium chloride is used to adjust the tonicity of the composition.
The compositions of the present invention may also be used to administer pharmaceutically active compounds. Such compounds include, but are not limited to, glaucoma therapeutics, analgesics, anti-inflammatory and anti-allergic drugs, and antimicrobial agents. More specific examples of pharmaceutically active compounds include betaxolol, timolol, pilocarpine, carbonic anhydrase inhibitors, and prostaglandins; a dopaminergic antagonist; postoperative antihypertensive agents such as p-aminocclonidine (alaclonidine); anti-infective agents such as ciprofloxacin, moxifloxacin, and tobramycin; non-steroidal and steroidal anti-inflammatory agents such as naproxen, diclofenac, nepafenac, suprofen, ketorolac, tetrahydrocortisol, and dexamethasone; dry eye therapeutic agents, for example, PDE4 inhibitors; and antiallergic drugs such as H1/H4 inhibitors, H4 inhibitors, olopatadine, or mixtures thereof.
It is also contemplated that the concentration of the ingredients comprising the formulations of the present invention may vary. One of ordinary skill in the art will appreciate that the concentration may vary depending on the addition, substitution, and/or subtraction of ingredients in a given formulation.
In certain embodiments, the compositions of the present invention may have a pH compatible with the intended use, and typically range from 4 (or about 4) to 10 (or about 10), optionally between 6 (or about 6) to 8 (to about 8), optionally between 6.5 (or about 6.5) to 7.5 (or about 7.5), or optionally between 6.8 (or about 6.8) to 7.2 (or about 7.2).
In certain embodiments, various conventional buffering agents may be employed, such as phosphates, borates, citrates, acetates, histidines, tris, bis-tris, and the like, and mixtures thereof. Borate buffers include boric acid and salts thereof, such as sodium or potassium borate. Potassium tetraborate or metaborate may also be used, which in solution produces boric acid or a borate salt. Hydrated salts, such as sodium borate decahydrate, may also be used. Phosphate buffers include phosphoric acid and its salts; for example, M2HPO4And MH2PO4, where M is an alkali metal such as sodium and potassium. Hydrated salts may also be used. In one embodiment of the invention, Na is used2HPO4.7H2O and NaH2PO2.H2O as a buffer. The term phosphate also includes compounds that produce phosphoric acid or phosphate in solution. In addition, organic counterions to the above-mentioned buffers can also be used. The concentration of the buffer typically varies between about 0.01 w/v% and 2.5 w/v%, more preferably between about 0.05 w/v% and about 0.5 w/v%.
In certain embodiments, the compositions of the present invention have a viscosity ranging from about 1cps to about 500cps, optionally from about 10cps to about 200cps, or optionally from about 10cps to about 100cps when measured using a TA Instrument AR2000 rheometer. The TA Instrument AR2000 rheometer should be used with the AR2000 flow test method of the TA rheologic Advantage software, the rheometer having a 40mm steel plate geometry; the viscosity range should be obtained by measuring the steady-state flow rate, which is controlled at a shear rate of 0 sec-1 to 200 sec-1.
In certain embodiments, the compositions of the present invention may be used as an eye drop solution, an eye wash solution, a contact lens lubricating and/or rewetting solution, a spray, a mist, or any other form of applying the composition to the eye.
The compositions of the present invention may also be used in the form of a wetting solution for contact lenses. In certain embodiments, the compositions of the present invention are sealable in blister packages as a wetting solution, and are also suitable for undergoing a sterilization process.
Examples of blister packages and sterilization techniques are disclosed in the following references, which are incorporated herein by reference in their entirety: U.S. patent D435,966; 4,691,820; 5,467,868, respectively; 5,704,468, respectively; 5,823,327, respectively; 6,050,398, 5,696,686; 6,018,931, respectively; 5,577,367, respectively; and 5,488,815. This part of the manufacturing process provides another method of treating an ophthalmic device with an anti-allergic agent by adding the anti-allergic agent to the solution prior to sealing the package, followed by sterilization of the package. This is the preferred method of treating ophthalmic devices with anti-allergic agents.
Sterilization may be performed at different temperatures and time periods. Preferred sterilization conditions range from about 8 hours at about 100 ℃ to about 0.5 minutes at about 150 ℃. More preferred sterilization conditions range from about 2.5 hours at about 115 ℃ to about 5.0 minutes at about 130 ℃. The most preferred sterilization conditions are at about 124 ℃ for about 18 minutes.
When used as a wetting solution, the composition of the present invention may be a water-based solution. Typical wetting solutions include, but are not limited to, saline solutions, other buffers, and deionized water. In certain embodiments, the wetting solution is an aqueous solution of deionized water or an aqueous salt solution containing salts including, but not limited to, sodium chloride, sodium borate, sodium phosphate, sodium hydrogen phosphate, sodium dihydrogen phosphate, or their corresponding potassium salts. These ingredients are typically combined to form a buffer solution comprising an acid and its conjugate base, such that the addition of the acid and base causes only a relatively minor change in pH. In certain embodiments, the pH of the wetting solution is as described above. The buffer may additionally comprise 2- (N-morpholino) ethanesulfonic acid (MES), sodium hydroxide, 2-bis (hydroxymethyl) -2,2',2 "-nitrilotriethanol, N-tris (hydroxymethyl) methyl-2-aminoethanesulfonic acid, citric acid, sodium citrate, sodium carbonate, sodium bicarbonate, acetic acid, sodium acetate, ethylenediaminetetraacetic acid, and the like, and combinations thereof. Preferably, the solution is a borate buffered saline solution or a phosphate buffered saline solution or deionized water. Particularly preferred solutions contain about 500ppm to about 18,500ppm sodium borate, most particularly preferably about 1000ppm sodium borate.
If any ingredients incorporated into the wetting solution undergo oxidative degradation, agents may be added to stabilize the wetting solution containing such ingredients. Such "oxidative stabilizers" include, but are not limited to, chelating agents (such as EDTA, Dequest, Desferal, silica), chitin derivatives (such as chitosan, cellulose and its derivatives, and N, N', N "-hexa (2-pyridyl) -1,3, 5-tris (aminomethyl) benzene), and certain macrocyclic ligands (such as crown ethers, ligands containing junctions and chains). See, David A.Leigh et al, Angew.Chem int. eds., 2001, Vol.40, No. 8, p.1538-1542, and Jean-Claude chamboron et al, Pure & appl.chem., 1990, Vol.62, No. 6, p.1027-1034. The oxidation stabilizer may include other compounds that inhibit oxidation, such as selected from the group consisting of: 2,2', 6,6' -hexa (1, 1-dimethylethyl) 4,4' - [ (2,4, 6-trimethyl-1, 3, 5-benzenetriyl) -trimethylene ] -trisphenol (Irganox 1330), 1,3, 5-tris [3, 5-bis (1, 1-dimethylethyl) 4-hydroxybenzyl ] -1H,3H,5H-1,3, 5-triazine-2, 4, 6-trione, pentaerythritol tetrakis [3- [3, 5-bis (1, 1-dimethylethyl) -4-hydroxyphenyl ] -propionate ], octadecyl-3- [3, 5-bis (1, 1-dimethylethyl) -4-hydroxyphenyl ] -propionate, Tris [2, 4-bis (1, 1-dimethylethyl) -phenyl ] -phosphite, 2 '-dioctadecyloxy) -5,5' -spirocyclic bis (1,3, 2-dioxolane), dioctadecyl disulfide, didodecyl-3, 3 '-thiodipropionate, dioctadecyl-3, 3' -thiodipropionate, butylhydroxytoluene, ethylenebis [3, 3-bis [3- (1, 1-dimethylethyl) -4-hydroxyphenyl ] butyrate ], and mixtures thereof. Preferred oxidation stabilizers are diethylenetriaminepentaacetic acid ("DTPA"), or salts of DTPA such as CaNa3DTPA, ZnNa3DTPA, and Ca2 DTPA. See U.S. patent application 60/783,557 entitled "Methods for Stabilizing oxygen reactive volatile Pharmaceutical Compositions" filed 2006, month 3, and day 17, and its corresponding non-provisional filed application, which are incorporated herein by reference in their entirety. In certain embodiments, the concentration of the oxidation stabilizer in the solution is from about 2.5 micromoles/liter to about 5000 micromoles/liter, optionally from about 20 micromoles/liter to about 1000 micromoles/liter, optionally from about 100 micromoles/liter to about 1000 micromoles/liter, or optionally from about 100 micromoles/liter to about 500 micromoles/liter.
In particular embodiments, the compositions of the present invention are formulated for administration at any frequency of administration, including weekly, once every five days, once every three days, once every two days, twice daily, three times daily, four times daily, five times daily, six times daily, eight times daily, hourly or more. This dosing frequency is also maintained for a variable duration of time, depending on the therapeutic needs of the user. The duration of a particular treatment regimen may vary from a single administration to a regimen that lasts for months or years. One of ordinary skill in the art will be familiar with determining a particular indicated treatment regimen.
Compositions and products comprising such compositions of the present invention can be prepared using methods well known to those of ordinary skill in the art.
Examples
Any compositions of the present invention described in the following examples illustrate specific embodiments of the compositions of the present invention, but are not intended to be limiting. Other modifications may be made by those skilled in the art without departing from the spirit and scope of the invention.
The following test methods were used in the examples:
example 1
To reduce blockages that may be caused by tight junction structures (i.e., those surface structures [ e.g., membranes or membrane barriers ] that typically inhibit chemical penetration into tissues), induction of mucin secretion in human corneal epithelial outer membrane 3D tissue was observed by contacting the corneal tissue with a growth medium (i.e., "treated" medium) containing Pichia anomala fermentation extract (Hyalurodine) such that the bottom cell layer of the corneal tissue (i.e., the cell layer that does not have tight junction structures that inhibit chemical penetration into tissues) was immersed in the growth medium. By contacting the basal cell layer of corneal tissue with a growth medium containing a Pichia anomala (Pichia anomala) fermentation extract, the extract can directly contact and move up into the intracorneal tissue without first having to cross any tight junctions or other surface barriers, thereby improving the bioavailability of Pichia anomala (Pichia anomala) into the corneal tissue cells.
Human corneal epithelial 3D tissue treated with Pichia anomala (hylauroda) fermentation extract (hylaurodine) at concentrations of 1.56mg/mL and 1.95mg/mL in growth medium showed increased MUC4 gene expression in human corneal epithelial 3D tissue.
Human corneal epithelial 3D tissue was purchased from MatTek corporation (Ashland, MA, USA). After receiving the human corneal epithelial 3D tissue, the tissue was incubated overnight in MatTek assay medium according to the manufacturer's instructions. Human corneal epithelial 3D tissue was divided into three treatment groups of three tissues each. Pichia anomala (Pichia anomala) fermentation extract (Hyalurodine) was added to the medium containing human corneal epithelial tissue of two of the treatment groups, respectively, to produce medium concentrations of 1.56mg/mL and 1.95mg/mL, respectively. Corneal epithelial tissue in all treatment groups was incubated for two days. Pichia anomala (Pichia anomala) fermentation extract was provided by Silab (st. viance France). Two days later, the human corneal epithelial 3D tissue was cut in half and half of the tissue was lysed in 350 μ L of lysis buffer consisting of 100 parts RLT buffer (RNeasy Mini kit, Qiagen, Valencia, CA) to one part 2-mercaptoethanol. RNA was extracted from the solution using the RNeasy Mini Kit (Qiagen, Valencia, Calif.) according to the manufacturer's instructions and eluted in 25. mu.L of RNase-free water.
Reverse Transcription (RT) was performed using the Applied Biosystems High Capacity Reverse Transcription Kit (ThermoFisher Scientific, Bridgewater, NJ). Gene expression assays for mucin-4 (MUC4), polymerase (RNA) II polypeptide A (POLR2A) and Master Mix were purchased from ThermoFisher Scientific (Bridgewater, NJ) and sold under the trade name TAQMAN. Use of
Master Mix (ThermoFisher Scientific, Bridgewater, NJ) performed the qPCR analysis and run the qPCR analysis on a real-time PCR system sold under the trade name QUANTSTUDIO 7Flex System (ThermoFisher Scientific, Bridgewater, NJ). Table of housekeeping genes relative to human POLR2AThe expression of the MUC4 gene is normalized. Fold changes were calculated and a two-tailed two-sample student's t-test (Microsoft Office Excel 2007; Microsoft, Redmond, WA, USA) WAs performed compared to untreated controls (UT). The results are shown in fig. 1, indicating that fold change of MUC4 in corneal tissue cells increases with increasing concentration of Pichia anomala (Pichia anomala) fermentation extract in the culture medium. An "untreated" sample was prepared according to the same procedure described in this example, except that the culture medium was not supplemented with Pichia anomala (Pichia anomala).
Example 2
Human corneal epithelial 3D tissue treated with Pichia anomala fermentation extract (Hyalurodine) containing concentrations of 0.39mg/mL, 0.78mg/mL, 1.56mg/mL, and 1.95mg/mL in growth medium showed increased MUC4 gene expression in human corneal epithelial 3D tissue. P < 0.05.
Human corneal epithelial 3D tissue was purchased from MatTek corporation (Ashland, MA, USA). After receiving the human corneal epithelial 3D tissue, the tissue was incubated overnight in MatTek assay medium according to the manufacturer's instructions. Human corneal epithelial 3D tissue was divided into five treatment groups of three tissues each. Pichia anomala (Pichia anomala) fermentation extract (Hyalurodine) was added to the medium containing human corneal tissue of four of the treatment groups, respectively, to produce medium concentrations of 0.39mg/mL, 0.78mg/mL, 1.56mg/mL, and 1.95mg/mL, respectively. Corneal epithelial tissue in all five treatment groups was incubated for two days. Pichia anomala (Pichia anomala) fermentation extract was provided by Silab (st. vision, France). Two days later, media was collected using human mucin-1 (CA15-3) enzyme-linked immunosorbent assay (ELISA) kit (EHMUC1, thermo fisher Scientific, Bridgewater, NJ) for determination of mucin 1 secretion following the manufacturer's protocol. To assess activity, colorimetric changes were measured using a microplate reader (SpectraMax M2E, Molecular Devices, Sunnyvale, Calif., USA). The assay employs standard enzyme-linked immunosorbent assay techniques, so that there is a linear correlation between mucin-1 concentration in the sample and colorimetric changes. A standard curve is generated with mucin-1 concentration as the x-axis and absorbance as the y-axis, indicating the corresponding mucin-1 concentration. The results are shown in fig. 2, indicating that mucin-1 production in corneal tissue cells increases with increasing environmental concentration of Pichia anomala (Pichia anomala) fermentation extract in the culture medium.
Example 3
Increased mucin-1 secretion in human corneal epithelial 3D tissue was shown when compositions of Pichia anomala extracts at concentrations of 1.95mg/mL, 7.8mg/mL, 19.5mg/mL, and 39mg/mL in PBS were topically administered to corneal tissue cells. P < 0.05.
Human corneal epithelial 3D tissue was purchased from MatTek corporation (Ashland, MA, USA). After receiving the human corneal epithelial 3D tissue, the tissue was incubated overnight in MatTek assay medium according to the manufacturer's instructions. Human corneal epithelial 3D tissue was divided into three treatment groups of three tissues each. Four concentrations of Pichia anomala (Hyalurodine) fermentation extract at 1.95mg/mL, 7.8mg/mL, 19.5mg/mL and 39mg/mL were suspended in Phosphate Buffered Saline (PBS) vehicle and applied topically to the corneal epithelial surface of four of the treatment groups, respectively. Corneal epithelial tissue in all five treatment groups was incubated for two days. Pichia anomala (Pichia anomala) fermentation extract was provided by Silab (st. vision, France). Two days later, media was collected using human mucin-1 (CA15-3) enzyme-linked immunosorbent assay (ELISA) kit (EHMUC1, thermo fisher Scientific, Bridgewater, NJ) for determination of mucin 1 secretion following the manufacturer's protocol. To assess activity, colorimetric changes were measured using a microplate reader (SpectraMax M2E, Molecular Devices, Sunnyvale, Calif., USA). The assay employs standard enzyme-linked immunosorbent assay techniques, so that there is a linear correlation between mucin-1 concentration in the sample and colorimetric changes. A standard curve is generated with mucin-1 concentration as the x-axis and absorbance as the y-axis, indicating the corresponding mucin-1 concentration. The results are shown in FIG. 3. (Kiwi fruit was used in FIG. 2 to represent Pichia anomala (Pichia anomala) fermented extract).
The results showed that increased production of mucin-1 in corneal tissue cells was observed after topical administration of compositions with concentrations of 1.95mg/mL, 7.8mg/mL, 19.5mg/mL, and 39mg/mL extracts of Pichia anomala (dissolved in PBS).
Example 4
Pichia anomala (Pichia anomala) fermented extract (Hyalurodine) induces hyaluronic acid secretion in human corneal epithelial 3D tissue when topically applied to corneal tissue cells. Without being limited by theory, it is believed that such topical administration requires the Pichia anomala (Pichia anomala) fermentation extract to diffuse through the tightly-connected structures of human corneal epithelial tissue (i.e., those structures [ e.g., membranes or membrane barriers ] that typically inhibit chemical penetration into the tissue) to reach the interior of the corneal epithelial tissue.
Human corneal epithelial 3D tissue was purchased from MatTek corporation (Ashland, MA, USA). After receiving the human corneal epithelial 3D tissue, the tissue was incubated overnight in MatTek assay medium according to the manufacturer's instructions. Human corneal epithelial 3D tissue was divided into five treatment groups of three tissues each. Four concentrations of Pichia anomala (hylauridine) fermentation extract in Phosphate Buffered Saline (PBS) vehicle of 1.95mg/mL, 7.8mg/mL, 19.5mg/mL and 39mg/mL were topically applied to the corneal epithelial surface of the four treatment groups, respectively (so that the Pichia anomala fermentation extract was delivered through the tight junction structure described above). Corneal epithelial tissue in all five treatment groups was incubated for two days. Pichia anomala (Pichia anomala) fermentation extract was provided by Silab (st. vision, France). Two days later, media was collected using the HA enzyme-linked immunosorbent assay (ELISA) kit (K-1200, Echelon, Salt Lake City, UT, USA) for determination of Hyaluronic Acid (HA) secretion according to the manufacturer's protocol. To assess activity, colorimetric changes were measured using a microplate reader (SpectraMax M2E, Molecular Devices, Sunnyvale, Calif., USA). The assay employs a competitive enzyme-linked immunosorbent assay technique, and therefore, there is an inverse correlation between the HA concentration in the sample and the colorimetric change. A standard curve is generated with HA concentration on the x-axis and absorbance on the y-axis, indicating the corresponding HA concentration. The results are shown in FIG. 4.
Although the results indicate that topical administration at the tested concentrations directionally indicates that HA production is induced in corneal cells, factors such as tight junction structures (or other surface membrane or membranous barriers) can reduce the concentration of Pichia anomala (Pichia anomala) reaching the internal corneal tissue. In such cases, embodiments of the present invention incorporating a permeation enhancer may be useful.
Example 5
In order to reduce the obstruction that may be caused by the tight junction structure (or membrane barrier) described above, induction of hyaluronic acid secretion in human corneal epithelial adventitia 3D tissue was observed by contacting the corneal tissue with a growth medium (i.e., a "treated" medium) containing a Pichia anomala fermentation extract (Hyalurodine) such that the bottom cell layer of the corneal tissue (i.e., the cell layer without the tight junction structure that inhibits chemical penetration into the tissue) was immersed in the growth medium. By contacting the basal cell layer of corneal tissue with a growth medium containing a Pichia anomala (Pichia anomala) fermentation extract, the extract can directly contact and move up into the intracorneal tissue without first having to cross any tight junctions or other surface barriers, thereby improving the bioavailability of Pichia anomala (Pichia anomala) into the corneal tissue cells.
Human corneal epithelial 3D tissue was purchased from MatTek corporation (Ashland, MA, USA). After receiving the human corneal epithelial 3D tissues, the tissues were incubated overnight in MatTek assay medium according to the manufacturer's instructions. Human corneal epithelial 3D tissue was divided into five treatment groups of three tissues each. Pichia anomala (Pichia anomala) fermented extract (Hyalurodine) was added to the medium containing human corneal epithelial tissue of four of the treatment groups, respectively, to produce medium concentrations of 0.39mg/mL, 0.78mg/mL, 1.56mg/mL, and 1.95mg/mL, respectively, to contact the basal cell layer of human corneal epithelial tissue. Corneal epithelial tissue in all five treatment groups was incubated for two days. Pichia anomala (Pichia anomala) fermentation extract was provided by Silab (st. vision, France). Two days later, media was collected using the HA enzyme-linked immunosorbent assay (ELISA) kit (K-1200, Echelon, Salt Lake City, UT, USA) for determination of Hyaluronic Acid (HA) secretion according to the manufacturer's protocol. To assess activity, colorimetric changes were measured using a microplate reader (SpectraMax M2E, Molecular Devices, Sunnyvale, Calif., USA). The assay employs a competitive enzyme-linked immunosorbent assay technique, and therefore, there is an inverse correlation between the HA concentration in the sample and the colorimetric change. A standard curve is generated with HA concentration on the x-axis and absorbance on the y-axis, indicating the corresponding HA concentration. The results are shown in FIG. 5.
The results show that at such tissue environmental concentrations of Pichia anomala (Pichia anomala) of at least 0.3mg/mL (i.e., the concentration of Pichia anomala extract contacting such internal corneal tissue cells [ e.g., corneal fluid level concentration ]), a statistically significant increase in HA production in corneal tissue cells was observed.
Example 6
Table 1 shows the components of such formulations (as shown in formulations 6A-6B), which can be incorporated as described below using conventional mixing techniques.
TABLE 1
Adjusting to osmotic pressure of 280mOsm/Kg-290mOsm/Kg
Adjusting to pH 7.2
Q.s to 100% w/w
For examples 6A-6B: sodium hyaluronate may be provided by contiro A.S (DOLNI, DOBROUC, CZECH REPUBLIC).
For examples 6A-6B: pichia anomala extract was provided by SILAB (SAINT VIANCE, FRANCE).
For examples 6A-6B: polysorbate 20 may be provided by Merck KGaA (DARMSTADT, GERMANY).
For examples 6A-6B: polysorbate 80 may be provided by Merck KGaA (DARMSTADT, GERMANY).
For example 6A: polyethylene glycol 400 can be provided by Clariant Produkte (Burgkirchen, GERMANY).
For examples 6A-6B: boric acid may be provided by Merck KGaA (DARMSTADT, GERMANY).
For examples 6A-6B: sodium borate may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 6A-6B: sodium chloride may be supplied by Caldic (DusseldoRF, GERMANY).
For examples 6A-6B: potassium chloride may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 6A-6B: calcium chloride dihydrate may be provided by Merck KGaA (DARMSTADT, GERMANY).
For examples 6A-6B: magnesium chloride may be provided by KGaA (DARMSTADT, GERMANY).
For examples 6A-6B: polyquaternium-42 (33% aqueous solution) may be supplied by DSM BIOMEDICAL (BERKELEY, CA, USA).
For examples 6A-6B: sodium chlorite dihydrate can be supplied by Oxychem (WICHITA, KS, USA).
For examples 6A-6B: the 1N sodium hydroxide may be supplied by VWR (RADPER, PA, USA).
For examples 6A-6B: the 1N hydrochloric acid may be supplied by VWR (RANDER, PA, USA).
Solution 6A can be prepared as follows：
1. To a 1500mL beaker was added 800 grams of purified water USP.
2. To the above material were added 10g of polysorbate 80 and 50g of polysorbate 20. The solution was mixed until both were completely mixed and dissolved.
3. To the above material was added 20.0g of Pichia anomala extract. The solution was mixed until the pichia anomala extract was dissolved.
4. The solution was filtered through a 0.45 micron filter and poured back into a 1500mL beaker.
5. To the solution obtained in step 4 was added 2.0 g of sodium hyaluronate. The solution was mixed to completely dissolve the sodium hyaluronate.
6. The following ingredients were then added in order, dissolving each ingredient and then adding the latter: 2.5 grams of polyethylene glycol 400, 6.0 grams of boric acid, 0.05 grams of sodium borate, 1.0 grams of potassium chloride, 0.06 grams of calcium chloride dihydrate, 0.06 grams of magnesium chloride, and 0.0015 grams of polyquaternium-42 (aqueous solution).
7. While mixing was continued, 0.14 grams of sodium chlorite dihydrate was added and mixed until dissolved.
8. The osmotic pressure of the formulation was measured and adjusted to 280mOsm/Kg with sodium chloride.
9. The pH of the formulation was adjusted to pH 7.2 using 1N sodium hydroxide and/or 1N hydrochloric acid.
10. The solution was adjusted to 1000.0 grams using purified water USP and mixed for 10 minutes to completely homogenize.
11. The solution was filtered using a 0.22 micron filter.
Solution 6B can be prepared as follows：
1. To a 1500mL beaker was added 800 grams of purified water USP.
2. To the above material were added 20g of polysorbate 10 and 100g of polysorbate 20. The solution was mixed until both were completely mixed and dissolved.
3. To the above material was added 50g of Pichia anomala extract. The solution was mixed until the pichia anomala extract was dissolved.
4. The solution was filtered through a 0.45 micron filter and poured back into a 1500mL beaker.
5. To the solution obtained in step 4 was added 1.5 g of sodium hyaluronate. The solution was mixed to completely dissolve the sodium hyaluronate.
6. The following ingredients were then added in order, dissolving each ingredient and then adding the latter: 6.0 grams boric acid, 0.05 grams sodium borate, 1.0 gram potassium chloride, 0.06 grams calcium chloride dihydrate, 0.06 grams magnesium chloride and 0.0015 grams polyquaternium-42 (aqueous solution).
7. While mixing was continued, 0.14 grams of sodium chlorite dihydrate was added and mixed until dissolved.
8. The osmotic pressure of the formulation was measured and adjusted to 280mOsm/Kg with sodium chloride.
9. The pH of the formulation was adjusted to pH 7.2 using 1N sodium hydroxide and/or 1N hydrochloric acid.
10. The solution was adjusted to 1000.0 grams using purified water USP and mixed for 10 minutes to completely homogenize.
11. The solution was filtered using a 0.22 micron filter.
Example 7
Table 2 shows the components of the formulations of the present invention (as shown in formulations 7A to 7B), which can be incorporated as described below using conventional mixing techniques.
TABLE 2
Adjusting to osmotic pressure of 280mOsm/Kg-290mOsm/Kg
Adjusting to pH 7.2
Q.s to 100.00% by volume
For examples 7A-7B: the Pichia anomala extract can be provided by SILAB (SAINT VIANCE, FRANCE).
For examples 7A-7B: polysorbate 20 may be provided by Merck KGaA (DARMSTADT, GERMANY).
For examples 7A-7B: polysorbate 80 may be provided by Merck KGaA (DARMSTADT, GERMANY).
For examples 7A-7B: boric acid may be provided by Merck KGaA (DARMSTADT, GERMANY).
For examples 7A-7B: sodium borate may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 7A-7B: sodium chloride may be supplied by Caldic (DusseldoRF, GERMANY).
For examples 7A-7B: potassium chloride may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 7A-7B: hypromellose E32910 may be supplied by DOW CHEMICAL (PLAQUEMINE, LOUISIANA, USA).
For examples 7A-7B: glycerol can be supplied by Emery Oleochemicals GmbH (DUSSELDORF, GERMANY).
For examples 7A-7B: disodium phosphate may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 7A-7B: sodium citrate may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 7A-7B: sodium lactate may be provided as sodium lactate (50% aqueous solution) by Merck KGaA (DARMSTADT, GERMANY).
For examples 7A-7B: glucose can be supplied by Roquette Freres (lastem, FRANCE).
For examples 7A-7B: glycine may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 7A-7B: ascorbic acid can be obtained from DSM Nutritional Products (DRAKEMYRE, SCOTLAND, UK).
For examples 7A-7B: polyquaternium 42 may be provided by DSM BIOMEDICAL (BERKELEY, CA) as Polyquaternium 42 (33% aqueous solution).
For examples 7A-7B: disodium edetate may be supplied by Merck NV/SA (OVERIJSE, BELGIUM).
For examples 7A-7B: the 1N sodium hydroxide may be supplied by VWR (RADPER, PA, USA).
For examples 7A-7B: the 1N hydrochloric acid may be supplied by VWR (RANDER, PA, USA).
For examples 7A-7B: sodium chlorite dihydrate can be supplied by Oxychem (WICHITA, KS, USA).
Solution 7A can be prepared as follows：
1. To a 1500mL beaker was added 800 grams of purified water USP.
2. To the above material were added 10g of polysorbate 80 and 30g of polysorbate 20. The solution was mixed until both were completely mixed and dissolved.
3. 10.0g of Pichia anomala extract was added to the above material. The solution was mixed until the pichia anomala extract was dissolved.
4. The solution was filtered through a 0.45 micron filter and poured back into a 1500mL beaker.
5. To the above solution was added 1.98 grams of hypromellose E3 Premium. The solution was mixed until hypromellose E3 Premium was dissolved.
6. The following ingredients were then added in order, dissolving each ingredient and then adding the latter: 2.50 grams of glycerol, 4.0 grams of boric acid, 0.22 grams of sodium borate, 0.27 grams of disodium phosphate, 4.00 grams of sodium citrate dihydrate, 1 gram of potassium chloride, 0.57 grams of sodium lactate (50% aqueous solution), 0.13 grams of magnesium chloride, 0.036 grams of glucose, 0.0002 grams of glycine, 0.0001 grams of ascorbic acid, 0.10 grams of disodium edetate, 0.030 grams of polyquaternium-42 (33% aqueous solution), and 0.14 grams of sodium chlorite.
7. The osmolality of the solution was measured and adjusted to 280mOsm with sodium chloride.
8. The pH of the solution was measured and adjusted to 7.2 with 1N sodium hydroxide and/or 1N hydrochloric acid.
9. The solution was brought to 1,000.00 g with purified water and mixed for 10 minutes.
10. The solution was filtered using a 0.22 micron filter.
Solution 7B can be prepared as follows：
1. To a 1500mL beaker was added 800 grams of purified water USP.
2. To the above material were added 10g of polysorbate 80 and 50g of polysorbate 20. The solution was mixed until both were completely mixed and dissolved.
3. To the above material was added 20.0g of Pichia anomala extract. The solution was mixed until the pichia anomala extract was dissolved.
4. The solution was filtered through a 0.45 micron filter and poured back into a 1500mL beaker.
5. To the above solution was added 1.98 grams of hypromellose E3 Premium. The solution was mixed until hypromellose E3 Premium was dissolved.
6. The following ingredients were then added in order, dissolving each ingredient and then adding the latter: 2.50 grams of glycerol, 4.0 grams of boric acid, 0.22 grams of sodium borate, 0.27 grams of disodium phosphate, 4.00 grams of sodium citrate dihydrate, 1 gram of potassium chloride, 0.57 grams of sodium lactate (50% aqueous solution), 0.13 grams of magnesium chloride, 0.036 grams of glucose, 0.0002 grams of glycine, 0.0001 grams of ascorbic acid, 0.05 grams of disodium edetate, 0.015 grams of polyquaternium-42 (33% aqueous solution), and 0.14 grams of sodium chlorite.
7. The osmolality of the solution was measured and adjusted to 280mOsm with sodium chloride.
8. The pH of the solution was measured and adjusted to 7.2 with 1N sodium hydroxide and/or 1N hydrochloric acid.
9. The solution was brought to 1,000.00 g with purified water and mixed for 10 minutes.
10. The solution was filtered using a 0.22 micron filter.
Example 8
Table 3 shows the components of such formulations (as shown in formulations 8A-8B), which can be incorporated as described below using conventional mixing techniques.
TABLE 3
Adjusting to osmotic pressure of 280mOsm/Kg-290mOsm/Kg
Adjusting to pH 7.2
Q.s to 100% w/w
For examples 8A-8B: sodium hyaluronate may be provided by contiro A.S (DOLNI, DOBROUC, CZECH REPUBLIC).
For examples 8A and 8B: the kiwifruit extract (pichia anomala extract) can be provided by SILAB (SAINT VIANCE, FRANCE).
For examples 8A-8B: polysorbate 20 may be provided by Merck KGaA (DARMSTADT, GERMANY).
For examples 8A-8B: polysorbate 80 may be provided by Merck KGaA (DARMSTADT, GERMANY).
For example 8A: polyethylene glycol 400 can be provided by Clariant Produkte (Burgkirchen, GERMANY).
For examples 8A-8B: boric acid may be provided by Merck KGaA (DARMSTADT, GERMANY).
For examples 8A-8B: sodium borate may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 8A-8B: sodium chloride may be supplied by Caldic (DusseldoRF, GERMANY).
For examples 8A-8B: potassium chloride may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 8A-8B: calcium chloride dihydrate may be provided by Merck KGaA (DARMSTADT, GERMANY).
For examples 8A-8B: magnesium chloride may be provided by KGaA (DARMSTADT, GERMANY).
For examples 8A-8B: polyquaternium-42 (33% aqueous solution) may be supplied by DSM BIOMEDICAL (BERKELEY, CA, USA).
For examples 8A-8B: sodium chlorite dihydrate can be supplied by Oxychem (WICHITA, KS, USA).
For examples 8A-8B: the 1N sodium hydroxide may be supplied by VWR (RADPER, PA, USA).
For examples 8A-8B: the 1N hydrochloric acid may be supplied by VWR (RANDER, PA, USA).
Solution 8A can be prepared as follows：
1. To a 1500mL beaker was added 800 grams of purified water USP.
2. To the above material were added 10g of polysorbate 80 and 50g of polysorbate 20. The solution was mixed until both were completely mixed and dissolved.
3. To the above material was added 20.0g of kiwi fruit extract. Mixing the solution until the kiwi fruit extract is dissolved.
4. The solution was filtered through a 0.45 micron filter and poured back into a 1500mL beaker.
5. To the solution obtained in step 4 was added 2.0 g of sodium hyaluronate. The solution was mixed to completely dissolve the sodium hyaluronate.
6. The following ingredients were then added in order, dissolving each ingredient and then adding the latter: 2.5 grams of polyethylene glycol 400, 6.0 grams of boric acid, 0.05 grams of sodium borate, 1.0 grams of potassium chloride, 0.06 grams of calcium chloride dihydrate, 0.06 grams of magnesium chloride, and 0.0015 grams of polyquaternium-42 (aqueous solution).
7. While mixing was continued, 0.14 grams of sodium chlorite dihydrate was added and mixed until dissolved.
8. The osmotic pressure of the formulation was measured and adjusted to 280mOsm/Kg with sodium chloride.
9. The pH of the formulation was adjusted to pH 7.2 using 1N sodium hydroxide and/or 1N hydrochloric acid.
10. The solution was adjusted to 1000.0 grams using purified water USP and mixed for 10 minutes to completely homogenize.
11. The solution was filtered using a 0.22 micron filter.
Solution 8B can be prepared as follows：
1. To a 1500mL beaker was added 800 grams of purified water USP.
2. To the above material were added 20g of polysorbate 10 and 100g of polysorbate 20. The solution was mixed until both were completely mixed and dissolved.
3. To the above material was added 50g of kiwi fruit extract. Mixing the solution until the kiwi fruit extract is dissolved.
4. The solution was filtered through a 0.45 micron filter and poured back into a 1500mL beaker.
5. To the solution obtained in step 4 was added 1.5 g of sodium hyaluronate. The solution was mixed to completely dissolve the sodium hyaluronate.
6. The following ingredients were then added in order, dissolving each ingredient and then adding the latter: 6.0 grams boric acid, 0.05 grams sodium borate, 1.0 gram potassium chloride, 0.06 grams calcium chloride dihydrate, 0.06 grams magnesium chloride and 0.0015 grams polyquaternium-42 (aqueous solution).
7. While mixing was continued, 0.14 grams of sodium chlorite dihydrate was added and mixed until dissolved.
8. The osmotic pressure of the formulation was measured and adjusted to 280mOsm/Kg with sodium chloride.
9. The pH of the formulation was adjusted to pH 7.2 using 1N sodium hydroxide and/or 1N hydrochloric acid.
10. The solution was adjusted to 1000.0 grams using purified water USP and mixed for 10 minutes to completely homogenize.
11. The solution was filtered using a 0.22 micron filter.
Example 9
Table 4 shows the components of the formulations of the present invention (as shown in formulations 9A to 9B), which can be incorporated as described below using conventional mixing techniques.
TABLE 4
Adjusting to osmotic pressure of 280mOsm/Kg-290mOsm/Kg
Adjusting to pH 7.2
Q.s to 100.00% by volume
For examples 9A and 9B: the kiwifruit extract (pichia anomala extract) can be provided by SILAB (SAINT VIANCE, FRANCE).
For examples 9A-9B: polysorbate 20 may be provided by Merck KGaA (DARMSTADT, GERMANY).
For examples 9A-9B: polysorbate 80 may be provided by Merck KGaA (DARMSTADT, GERMANY).
For examples 9A-9B: boric acid may be provided by Merck KGaA (DARMSTADT, GERMANY).
For examples 9A-9B: sodium borate may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 9A-9B: sodium chloride may be supplied by Caldic (DusseldoRF, GERMANY).
For examples 9A-9B: potassium chloride may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 9A-9B: hypromellose E32910 may be supplied by DOW CHEMICAL (PLAQUEMINE, LOUISIANA, USA).
For examples 9A-9B: glycerol can be supplied by Emery Oleochemicals GmbH (DUSSELDORF, GERMANY).
For examples 9A-9B: disodium phosphate may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 9A-9B: sodium citrate may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 9A-9B: sodium lactate may be provided as sodium lactate (50% aqueous solution) by Merck KGaA (DARMSTADT, GERMANY).
For examples 9A-9B: glucose can be supplied by Roquette Freres (lastem, FRANCE).
For examples 9A-9B: glycine may be supplied by Merck KGaA (DARMSTADT, GERMANY).
For examples 9A-9B: ascorbic acid can be obtained from DSM Nutritional Products (DRAKEMYRE, SCOTLAND, UK).
For examples 9A-9B: polyquaternium 42 may be provided by DSM BIOMEDICAL (BERKELEY, CA) as Polyquaternium 42 (33% aqueous solution).
For examples 9A-9B: disodium edetate may be supplied by Merck NV/SA (OVERIJSE, BELGIUM).
For examples 9A-9B: the 1N sodium hydroxide may be supplied by VWR (RADPER, PA, USA).
For examples 9A-9B: the 1N hydrochloric acid may be supplied by VWR (RANDER, PA, USA).
For examples 9A-9B: sodium chlorite dihydrate can be supplied by Oxychem (WICHITA, KS, USA).
Solution 9A may be prepared as follows：
1. To a 1500mL beaker was added 800 grams of purified water USP.
2. To the above material were added 10g of polysorbate 80 and 30g of polysorbate 20. The solution was mixed until both were completely mixed and dissolved.
3. To the above material was added 10.0g of kiwi fruit extract. Mixing the solution until the kiwi fruit extract is dissolved.
4. The solution was filtered through a 0.45 micron filter and poured back into a 1500mL beaker.
5. To the above solution was added 1.98 grams of hypromellose E3 Premium. The solution was mixed until hypromellose E3 Premium was dissolved.
6. The following ingredients were then added in order, dissolving each ingredient and then adding the latter: 2.50 grams of glycerol, 4.0 grams of boric acid, 0.22 grams of sodium borate, 0.27 grams of disodium phosphate, 4.00 grams of sodium citrate dihydrate, 1 gram of potassium chloride, 0.57 grams of sodium lactate (50% aqueous solution), 0.13 grams of magnesium chloride, 0.036 grams of glucose, 0.0002 grams of glycine, 0.0001 grams of ascorbic acid, 0.10 grams of disodium edetate, 0.030 grams of polyquaternium-42 (33% aqueous solution), and 0.14 grams of sodium chlorite.
7. The osmolality of the solution was measured and adjusted to 280mOsm with sodium chloride.
8. The pH of the solution was measured and adjusted to 7.2 with 1N sodium hydroxide and/or 1N hydrochloric acid.
9. The solution was brought to 1,000.00 g with purified water and mixed for 10 minutes.
10. The solution was filtered using a 0.22 micron filter.
Solution 9B can be prepared as follows：
1. To a 1500mL beaker was added 800 grams of purified water USP.
2. To the above material were added 10g of polysorbate 80 and 50g of polysorbate 20. The solution was mixed until both were completely mixed and dissolved.
3. To the above material was added 20.0g of kiwi fruit extract. Mixing the solution until the kiwi fruit extract is dissolved.
4. The solution was filtered through a 0.45 micron filter and poured back into a 1500mL beaker.
5. To the above solution was added 1.98 grams of hypromellose E3 Premium. The solution was mixed until hypromellose E3 Premium was dissolved.
6. The following ingredients were then added in order, dissolving each ingredient and then adding the latter: 2.50 grams of glycerol, 4.0 grams of boric acid, 0.22 grams of sodium borate, 0.27 grams of disodium phosphate, 4.00 grams of sodium citrate dihydrate, 1 gram of potassium chloride, 0.57 grams of sodium lactate (50% aqueous solution), 0.13 grams of magnesium chloride, 0.036 grams of glucose, 0.0002 grams of glycine, 0.0001 grams of ascorbic acid, 0.05 grams of disodium edetate, 0.015 grams of polyquaternium-42 (33% aqueous solution), and 0.14 grams of sodium chlorite.
7. The osmolality of the solution was measured and adjusted to 280mOsm with sodium chloride.
8. The pH of the solution was measured and adjusted to 7.2 with 1N sodium hydroxide and/or 1N hydrochloric acid.
9. The solution was brought to 1,000.00 g with purified water and mixed for 10 minutes.
10. The solution was filtered using a 0.22 micron filter.
Embodiments of the invention：
1. A microemulsion composition or microemulsion for use in treating the eye comprising:
i) one or more extracts or extract sources of pichia; and
ii) an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
2. The composition according to embodiment 1 (or any one of the following embodiments), wherein the pichia genus is selected from pichia anomala, pichia mondii, pichia norwegiae, pichia ohmer, and mixtures thereof.
3. The composition according to embodiments 1 and/or 2 (or any of the following embodiments), wherein the pichia genus is pichia anomala.
4. The composition according to any one or combination of embodiments 1-3 (or any one of the following embodiments), wherein the one or more extracts or extract sources of pichia are present at a concentration of about 0.01% to about 100% by weight of the total composition.
5. The composition of any one or combination of embodiments 1-4 (or any one of the following embodiments), wherein the one or more extracts or extract sources of pichia are present at a concentration of about 0.05% to about 95% by weight of the total composition.
6. The composition according to any one or combination of embodiments 1-5 (or any one of the following embodiments), wherein the one or more extracts or extract sources of pichia are present at a concentration of about 0.1% to about 90% by weight of the total composition.
7. The composition of any one or combination of embodiments 1-6 (or any one of the following embodiments), comprising a penetration enhancer.
8. The composition of any one or combination of embodiments 1-7 (or any one of the following embodiments), wherein the penetration enhancer is present at a concentration of about 0.01% to about 20% (w/v) of the overall composition.
9. The composition of any one or combination of embodiments 1-8 (or any one of the following embodiments), wherein the penetration enhancer is present at a concentration of about 0.1% to 10% (w/v) of the overall composition.
10. The composition of any one or combination of embodiments 1-9 (or any one of the following embodiments), wherein the penetration enhancer is present at a concentration of about 0.25% to 5% (w/v) of the overall composition.
11. The composition of any one or combination of embodiments 1-10 (or any one of the following embodiments), wherein the penetration enhancer is selected from the group consisting of polyoxyethylene, polyoxyethylene ethers of fatty acids, sorbitan monooleate, sorbitan monolaurate, polyoxyethylene sorbitan monolaurate, fusidic acid and derivatives thereof, EDTA, disodium ethylenediaminetetraacetate, cholic acid, deoxycholic acid, glycocholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium cholate, sodium glycocholate, sodium deoxycholate, sodium taurocholate, sodium glycodeoxycholate, sodium taurodeoxycholate, chenodeoxycholic acid, ursodeoxycholic acid, saponin, glycyrrhizic acid, ammonium glycyrrhizinate, quaternary ammonium decahydrocarbide bromide, and dodecyltrimethyl ammonium bromide, Or mixtures of any of the above.
12. The composition of any one or combination of embodiments 1-11 (or any one of the following embodiments), wherein the pichia extract comprises oligosaccharides and polysaccharides having a weight average molecular weight of about 180Da to about 800,000 Da.
13. The composition of any one or combination of embodiments 1-12 (or any one of the following embodiments), wherein the pichia extract comprises oligosaccharides and polysaccharides having an average degree of polymerization of DP 1 to DP 4444.
14. A method for producing/releasing/delivering/secreting mucin from and/or in a cornea, comprising the step of administering a microemulsion composition comprising:
i) one or more extracts or extract sources of pichia; and
ii) optionally, an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
15. The method of embodiment 14 (or any of the following embodiments), wherein the pichia genus is selected from pichia anomala, pichia mondii, pichia norwegiae, pichia ohmer, and mixtures thereof.
16. The method according to embodiments 14 and/or 15 (or any of the following embodiments), wherein the pichia genus is pichia anomala.
17. A method for maintaining a concentration of MU5AC in tear fluid in a range of equal to or greater than 8 ng to 15 ng/mg protein comprising the step of administering a microemulsion composition comprising:
i) one or more extracts or extract sources of pichia; and
ii) optionally, an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
18. A method for treating a patient suffering from symptoms of reduced or low level production/release/delivery/excretion of mucin from and/or in the cornea, comprising the step of topically administering to the eye of the patient a microemulsion composition comprising:
i) one or more extracts or extract sources of pichia; and
ii) optionally, an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
19. A method for promoting wound healing or increasing the rate of healing in and/or on the eye of a patient comprising the step of administering a microemulsion composition comprising:
i) one or more extracts or extract sources of pichia; and
ii) optionally, an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
20. A method for improving the antimicrobial properties of tears of a patient comprising the step of administering a microemulsion composition comprising:
i) one or more extracts or extract sources of pichia; and
ii) optionally, an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
21. A method for treating a patient suffering from reduced or low level production/release/delivery/excretion symptoms of hyaluronic acid from and/or in the cornea, comprising the step of topically administering to the eye of the patient a microemulsion composition comprising:
i) a safe and effective amount of one or more extracts or extract sources of pichia to achieve a pichia extract concentration in corneal effusion in corneal tissue of an eye of at least about 0.3 mg/ml;
ii) optionally, a safe and effective amount of a penetration enhancer; and
iii) optionally, an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
22. The method of embodiment 21 (or any of the following embodiments), wherein the pichia extract in the composition comprises a weight average molecular weight of about
Oligosaccharides and polysaccharides of 180Da to about 800,000 Da.
23. The method according to embodiment 21 and/or 22 (or any of the following embodiments), wherein the pichia extract in the composition comprises oligosaccharides and polysaccharides having an average degree of polymerization of DP 1 to DP 4444.
24. The method of any one or combination of embodiments 21-23 (or any one of the following embodiments), wherein the composition comprises a penetration enhancer.
25. The method of any one or combination of embodiments 21-24 (or any one of the following embodiments), wherein the penetration enhancer is present at a concentration of about 0.01% to about 20% (w/v) of the overall composition.
26. The method of any one or combination of embodiments 21-25 (or any one of the following embodiments), wherein the penetration enhancer is present at a concentration of about 0.1% to 10% (w/v) of the overall composition.
27. The method of any one or combination of embodiments 21-26 (or any one of the following embodiments), wherein the penetration enhancer is present at a concentration of about 0.25% to 5% (w/v) of the overall composition.
28. The method of any one or combination of embodiments 21-27 (or any one of the following embodiments), wherein the penetration enhancer is selected from the group consisting of polyoxyethylene, polyoxyethylene ethers of fatty acids, sorbitan monooleate, sorbitan monolaurate, polyoxyethylene sorbitan monolaurate, fusidic acid and derivatives thereof, EDTA, disodium ethylenediaminetetraacetate, cholic acid, deoxycholic acid, glycocholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium cholate, sodium glycocholate, sodium deoxycholate, sodium taurocholate, sodium glycodeoxycholate, sodium taurodeoxycholate, chenodeoxycholic acid, ursodeoxycholic acid, saponin, glycyrrhizic acid, ammonium glycyrrhizinate, quaternary ammonium decahydrocarbide bromide, and dodecyltrimethyl ammonium bromide, Or mixtures of any of the above.
29. The method of any one or combination of embodiments 21-28 (or any one of the following embodiments), wherein the composition is administered when the concentration of hyaluronic acid in the patient's tear fluid is less than about 10 ng/mg protein.
30. The method of any one or combination of embodiments 21-29 (or any one of the following embodiments), wherein the composition is administered when the concentration of hyaluronic acid in the patient's tear fluid is less than about 15 ng/mg protein.
31. The method of any one or combination of embodiments 21-30 (or any one of the following embodiments), wherein the composition is administered when the concentration of hyaluronic acid in the patient's tear fluid is less than about 20 ng/mg protein.
32. The method of any one or combination of embodiments 21-31 (or any one of the following embodiments), wherein the composition is administered when the concentration of hyaluronic acid in the patient's tear fluid is less than about 25 ng/mg protein.
33. The method of any one or combination of embodiments 21-32 (or any one of the following embodiments), wherein the composition is administered to the eye of the patient to raise the concentration of hyaluronic acid in the tear fluid of the patient to equal to or greater than about 10 ng/mg protein.
34. The method of any one or combination of embodiments 21-33 (or any one of the following embodiments), wherein the composition is administered to the eye of the patient to raise the concentration of hyaluronic acid in the tear fluid of the patient to equal to or greater than about 15 ng/mg protein.
35. The method of any one or combination of embodiments 21-34 (or any one of the following embodiments), wherein the composition is administered to the eye of the patient to raise the concentration of hyaluronic acid in the tear fluid of the patient to equal to or greater than about 20 ng/mg protein.
36. The method of any one or combination of embodiments 21-35 (or any one of the following embodiments), wherein the composition is administered to the eye of the patient to raise the concentration of hyaluronic acid in the tear fluid of the patient to equal to or greater than about 25 ng/mg protein.
Claims (13)
1. A microemulsion composition for treating an eye comprising:
i) one or more extracts or extract sources of the genus Pichia (Pichia); and
ii) an ophthalmically acceptable carrier
Wherein the microemulsion droplets or particles have a particle size of less than
Is measured.
2. The composition of claim 1, wherein the Pichia genus is selected from the group consisting of Pichia anomala (Pichia anomala), Pichia guilliermondii (Pichia guilliermondii), Pichia norwegiae (Pichia norvegensis), Pichia ohmeri (Pichia ohmeri), and mixtures thereof.
3. The composition of claim 2, wherein the pichia genus is pichia anomala.
4. The composition of claim 1, wherein the one or more extracts or extract sources of the genus pichia are present at a concentration of from about 0.001% to about 100% by weight of the total composition.
5. The composition of claim 1, wherein the one or more extracts or extract sources of the genus pichia are present at a concentration of from about 0.005% to about 95% by weight of the total composition.
6. The composition of claim 1, wherein the one or more extracts or extract sources of the genus pichia are present at a concentration of from about 0.01% to about 90% by weight of the total composition.
7. The composition of claim 1, comprising a penetration enhancer.
8. The composition of claim 7, wherein the penetration enhancer is present at a concentration of about 0.01% to about 20% (w/v) of the total composition.
9. The composition of claim 8, wherein the penetration enhancer is present at a concentration of about 0.1% to 10% (w/v) of the total composition.
10. The composition of claim 9, wherein the penetration enhancer is present at a concentration of about 0.25% to 5% (w/v) of the total composition.
11. The composition of claim 7, wherein the penetration enhancer is selected from polyoxyethylene, polyoxyethylene ethers of fatty acids, sorbitan monooleate, sorbitan monolaurate, polyoxyethylene sorbitan monolaurate, fusidic acid and its derivatives, EDTA, disodium ethylenediaminetetraacetate, cholic acid, deoxycholic acid, glycocholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium cholate, sodium glycocholate, sodium deoxycholate, sodium taurocholate, sodium glycodeoxycholate, chenodeoxycholic acid, ursodeoxycholic acid, saponin, glycyrrhizic acid, ammonium glycyrrhizinate, decahydrocarbyl quaternary ammonium bromide, and dodecyltrimethylammonium bromide, or a mixture of any of the foregoing.
12. The composition of claim 1, wherein the pichia extract comprises oligosaccharides and polysaccharides having a weight average molecular weight of about 180Da to about 800,000 Da.
13. The composition of claim 1, wherein the pichia extract comprises oligosaccharides and polysaccharides having an average degree of polymerization of DP 1 to DP 4444.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962937458P | 2019-11-19 | 2019-11-19 | |
| US201962937473P | 2019-11-19 | 2019-11-19 | |
| US62/937473 | 2019-11-19 | ||
| US62/937458 | 2019-11-19 | ||
| US17/099185 | 2020-11-16 | ||
| US17/099,185 US11969451B2 (en) | 2019-11-19 | 2020-11-16 | Compositions and methods for treating the eye |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112933118A true CN112933118A (en) | 2021-06-11 |
Family
ID=75964158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011302835.4A Pending CN112933118A (en) | 2019-11-19 | 2020-11-19 | Compositions and methods for treating the eye |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP2021080253A (en) |
| KR (1) | KR20210061297A (en) |
| CN (1) | CN112933118A (en) |
| AU (2) | AU2020273321A1 (en) |
| BR (1) | BR102020023560A8 (en) |
| CA (1) | CA3100032A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117268877A (en) * | 2023-11-21 | 2023-12-22 | 军科正源（北京）药物研究有限责任公司 | Method for detecting nerve growth factor in human tear and method for treating tear |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883469A (en) * | 2006-05-26 | 2006-12-27 | 朱啟婉 | An ocular microemulsion containing Vitamin A and Vitamin E and preparation method thereof |
| CN102994500A (en) * | 2008-10-22 | 2013-03-27 | 夸克医药公司 | Methods for treating eye disorders |
| CN106692029A (en) * | 2015-11-06 | 2017-05-24 | 强生消费者公司 | Topical gel cream composition |
| CN106890114A (en) * | 2015-12-17 | 2017-06-27 | 强生消费者公司 | Topical compositions comprising Pichia anomala and chicory root extract |
| CN108210378A (en) * | 2016-12-12 | 2018-06-29 | 强生消费者公司 | Topical compositions containing glycerine and yeast extract |
| CN108697635A (en) * | 2016-02-08 | 2018-10-23 | 索夫特意大利公司 | Ophthalmic composition for treating eye disease related with kerato-conjunctival surface modification |
-
2020
- 2020-11-18 JP JP2020191522A patent/JP2021080253A/en active Pending
- 2020-11-18 BR BR102020023560A patent/BR102020023560A8/en unknown
- 2020-11-19 CN CN202011302835.4A patent/CN112933118A/en active Pending
- 2020-11-19 KR KR1020200155844A patent/KR20210061297A/en unknown
- 2020-11-19 CA CA3100032A patent/CA3100032A1/en active Pending
- 2020-11-19 AU AU2020273321A patent/AU2020273321A1/en not_active Abandoned
-
2022
- 2022-11-03 AU AU2022263530A patent/AU2022263530A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883469A (en) * | 2006-05-26 | 2006-12-27 | 朱啟婉 | An ocular microemulsion containing Vitamin A and Vitamin E and preparation method thereof |
| CN102994500A (en) * | 2008-10-22 | 2013-03-27 | 夸克医药公司 | Methods for treating eye disorders |
| CN104857526A (en) * | 2008-10-22 | 2015-08-26 | 夸克制药公司 | Method for treating oculopathy |
| CN106692029A (en) * | 2015-11-06 | 2017-05-24 | 强生消费者公司 | Topical gel cream composition |
| CN106890114A (en) * | 2015-12-17 | 2017-06-27 | 强生消费者公司 | Topical compositions comprising Pichia anomala and chicory root extract |
| CN108697635A (en) * | 2016-02-08 | 2018-10-23 | 索夫特意大利公司 | Ophthalmic composition for treating eye disease related with kerato-conjunctival surface modification |
| CN108210378A (en) * | 2016-12-12 | 2018-06-29 | 强生消费者公司 | Topical compositions containing glycerine and yeast extract |
Non-Patent Citations (1)
| Title |
|---|
| 顾其胜: "《眼手术并发症原因与处理》", 第二军医大学出版社, pages: 306 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117268877A (en) * | 2023-11-21 | 2023-12-22 | 军科正源（北京）药物研究有限责任公司 | Method for detecting nerve growth factor in human tear and method for treating tear |
| CN117268877B (en) * | 2023-11-21 | 2024-02-20 | 军科正源（北京）药物研究有限责任公司 | Method for detecting nerve growth factor in human tear and method for treating tear |
Also Published As
| Publication number | Publication date |
|---|---|
| BR102020023560A8 (en) | 2023-02-07 |
| JP2021080253A (en) | 2021-05-27 |
| KR20210061297A (en) | 2021-05-27 |
| AU2022263530A1 (en) | 2022-12-08 |
| BR102020023560A2 (en) | 2021-10-13 |
| CA3100032A1 (en) | 2021-05-19 |
| AU2020273321A1 (en) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11357805B2 (en) | Compositions and methods for treating the eye | |
| AU2022246418B2 (en) | Compositions and methods for treating the eye | |
| CN115671090A (en) | Compositions and methods for treating the eye | |
| US11878042B2 (en) | Compositions and methods for treating the eye | |
| US11878041B2 (en) | Compositions and methods for treating the eye | |
| CN112823789B (en) | Compositions and methods for treating eyes | |
| US10966948B2 (en) | Compositions and methods for treating the eye | |
| AU2022263530A1 (en) | Compositions and methods for treating the eye | |
| EP3824877A1 (en) | Compositions and methods for treating the eye | |
| US11969451B2 (en) | Compositions and methods for treating the eye | |
| RU2795913C2 (en) | Compositions and methods for treating eye disorders | |
| RU2793736C2 (en) | Compositions and methods for eye treatment | |
| RU2802365C2 (en) | Compositions and methods of treating eye disorders | |
| RU2802625C2 (en) | Compositions and methods of treating eye disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40056094 Country of ref document: HK |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220623 Address after: California, USA Applicant after: Johnson & Johnson surgical vision Co. Address before: new jersey Applicant before: JOHNSON & JOHNSON CONSUMER COMPANIES, Inc. |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |